

POSTGRADUATE HONORS AND AWARDS

1989 - 1990	Scholarship for best performance in medical studies Sackler Medical School, Tel-Aviv University, Israel
1991 - 1992	Scholarship for best performance in medical studies Sackler Medical School, Tel-Aviv University, Israel
1-4/1994	Internal Medicine scholarship Michael Reese Hospital, Chicago, IL
2003	Travel scholarship 10 th Conference on Retroviruses and Opportunistic Infections Boston, MA
2010	M.A. ad eundem Brown University, Providence, RI, USA
2014	Annual Bruce M. Selya Award for Research Excellence; Lifespan
2018	Beckwith Family Award for Outstanding Teaching; Brown University

MILITARY SERVICE Israeli Defense Forces, Captain, 1983-1987

PROFESSIONAL LICENSES

1995	License to practice Medicine, Israel
1999	Internal Medicine Specialty License, Israel
2005-2007	Training physician License, RI, USA
2007 -	Medical Physician License, PA, USA
2009 -	Academic Faculty Medical License, RI, USA

BOARD CERTIFICATION

1994	USMLE Part II
1995	USMLE Part I
1998	ECFMG Indefinite Certificate
1999	Board Certification, Internal Medicine, Israel
2004	USMLE Part III
2010	American Academy of HIV Medicine Specialist

ACADEMIC APPOINTMENTS

- 1999- 2005 Instructor of Medicine
Sackler Medical School
Tel-Aviv University
Israel
- 2005- 2009 Assistant Professor of Medicine (Research)
Brown University Alpert Medical School
Providence, RI
- 2009- 2011 Assistant Professor of Medicine, Research Scholar
Brown University Alpert Medical School
Providence, RI
- 2011- Associate Professor of Medicine, Research Scholar
Brown University Alpert Medical School
Providence, RI
- 2017 - Professor of Medicine, Research Scholar
Brown University Alpert Medical School
Providence, RI

HOSPITAL APPOINTMENTS

- 1995 - 1999 Residency in Internal Medicine
Sheba Medical Center/Tel Aviv University
Israel
- 2007-2008 Research Associate
Lifespan
Providence, RI
- 2008 - Faculty Member
Division of Infectious Diseases
University Medicine Foundation
Providence, RI
- 2009 - Attending Physician
The Miriam Hospital
Providence, RI
- 2009 - Attending Physician
Rhode Island Hospital
Providence, RI

OTHER APPOINTMENTS AND ACTIVITIES

Membership in Guidelines, Study Sections, Steering Committees, Advisory and Editorial Boards

- 2004 Reviewer, External Peer Review Panel; The National Center for HIV, STD, and TB
Prevention (NCHDTP);
Centers for Diseases Control and Prevention (CDC), Atlanta, GA

- 2005 - Member, Steering Committee, TAQAS (TREAT Asia Quality Assessment Scheme)
- 2006 - Member, Steering Committee
- 2011 TASER (TREAT Asia Surveillance to Evaluate Resistance)
- 2009 Member, Scientific Advisory Board
LAASER (Linked Asia-Africa Surveillance to Evaluate Resistance).
- 2010 Reviewer, Special Emphasis Panel Grant Review Study Section
National Institute of Health, Bethesda, MD
- 2012 Reviewer, Fogarty International Center Grant Review for foreign investigators to begin
basic science research careers (FIRCA and GRIPS) Study Section,
May 31 to June 1, National Institute of Health, Bethesda, MD
- 2013 Reviewer, U.S.-China Program for Biomedical Collaborative Research (R01) Study
Section, January 24-25, National Institutes of Health, Bethesda, MD
- 2013 Reviewer, AIDS Clinical Studies and Epidemiology Study Section (ACE), November
17, National Institutes of Health, Bethesda, MD
- 2013- Editorial Board Member;
2016 Virulence
- 2013 - Editorial Board Member; Journal of the International AIDS Society
- 2013 - Member, AMPATH Research Executive Committee
- 2014 Reviewer, Small Business Innovation Research (SBIR): "Simple, inexpensive assay
for 5 common HIV resistance mutations", February 2014, NIH, Bethesda, MD
- 2014 Reviewer, AIDS Clinical Studies and Epidemiology Study Section (ACE), November 5;
National Institutes of Health, Bethesda, MD
- 2015 Reviewer, AIDS Clinical Studies and Epidemiology Study Section (ACE), March 4;
National Institutes of Health, San Antonio, TX
- 2015 External Advisory Committee Member, University of Washington Center for AIDS
Research; July 23-24, Seattle, WA
- 2015 - Chartered Member, AIDS Clinical Studies and Epidemiology Study Section (ACE),
National Institutes of Health, United States
- 2016 - Panel Member, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected
Adults and Adolescents; Department of Health and Human Services (DHHS)
- 2017 World Health Organization External Review Group (ERG) to develop guidelines on
public health responses to elevated levels of pre-treatment HIV drug resistance
- 2017 - Co-Leader, Viral Failure section, Guidelines for the Use of Antiretroviral Agents in
HIV-1-Infected Adults and Adolescents; Department of Health and Human Services
(DHHS)
- 2018 - Deputy Editor, Journal of the International AIDS Society
- 2018 - Member, American Academy for HIV Medicine, New England Chapter,
Steering Committee

OTHER APPOINTMENTS AND ACTIVITIES

- 2001 Co-Founder and Member; The HIV Non-Subtype B Working Group; an international collaboration of HIV researchers in 15 sites, 12 countries and 4 continents to study HIV diversity and drug resistance
- 2003 International conference organizer: 9th International Workshop on Virus Evolution and Molecular Epidemiology. Stanford University, Stanford, California, USA. August 13-23
- 2004 International workshop organizer and Faculty: TREAT Asia Workshop on HIV Drug Resistance. Chulalongkorn University, Bangkok, Thailand
- 2004 - Consultant
2011 TREAT Asia Network
- 2004 – Consultant
2010 World Health Organization Global HIV Drug Resistance Surveillance Network
- 2005 Organizer and Faculty, HIV Drug Resistance Workshop, YRG Care, Chennai, India
- 2005 - Member, AIDS Clinical Trials Group, Study 5077
- 2007 Member, AIDS Clinical Trials Group Scientific Agenda Steering Committee
International HIV Drug Resistance Research
- 2007 Grant reviewer, The National Medical Research Council (Singapore)
- 2008 - Director of Research, Brown University-Kenya Program
- 2008 - Research Co-Director, Infectious Diseases Fellowship Program, Brown University
2017
- 2009 Assessment for promotion of a candidate for the rank of Clinical Senior Lecturer, Tel-Aviv University, Israel
- 2010 - Co-Director, Basic Science Working Group
AMPATH (Academic Model Providing Access to Healthcare) Consortium
- 2010 - Director, The Miriam Hospital HIV Drug Resistance Laboratory
- 2011 Grant reviewer, The South African Medical Research Council
- 2012 Writing Team Chair
AIDS Clinical Trials Group, Study 5077
- 2012- Member
AIDS Clinical Trials Group, Study 5175
- 2012- Writing Team Chair of Drug Resistance sub-Studies
AIDS Clinical Trials Group, Study 5175
- 2012 Assessment for promotion of a candidate to the rank of Associate Professor, Swiss Federal Institute of Technology, Basel, Switzerland.
- 2014 Abstract Reviewer; 20th International AIDS Society Conference, July 20-25, Melbourne, Australia

- 2014 Abstract Mentor, 20th International AIDS Conference, July 20-25 2014, Melbourne, Australia
- 2014 Grant Reviewer, Genome Canada, Genomic Applications Partnership Program, Ottawa, ON, Canada
- 2015 Assessment for promotion of a candidate for the rank of Clinical Senior Lecturer, Tel-Aviv University, Israel
- 2015 Abstract Reviewer; 8th International AIDS Society Conference, July 19-22, Vancouver, Canada
- 2015 Member, World Health Organization committee for HIV drug resistance dry panel for sequence analyses
- 2015 Assessment for promotion of a candidate to the rank of Professor, National Research Foundation (NRF), South Africa
- 2015 - Member, Providence-Boston Center for AIDS Research Executive Committee
- 2015 - Co-Director, Providence-Boston Center for AIDS Research Basic and Translational Science Core
- 2016 Abstract Reviewer; 21st International AIDS Conference, July 18-22, Durban, South Africa
- 2016 Evaluation of a Rated Researcher for the National Research Foundation (NRF), South Africa
- 2017 Abstract Reviewer; 9th International AIDS Society Conference, July 23-26, Paris, France
- 2017 - Member, Division of Infectious Diseases Mentoring Committee, Brown University
- 2017 Assessment for promotion of a candidate for the rank of Senior Lecturer, Tel-Aviv University, Israel
- 2017 Assessment for promotion of a candidate for the rank of Assistant Professor (Tenure Track), University of North Carolina, Chapel Hill
- 2018 Abstract Reviewer; 22nd International AIDS Conference, July 22-27, Amsterdam, Netherlands

UNIVERSITY COMMITTEES

- 2005 - Member
Brown University/Kenya Program Advisory Committee
- 2008 - Member, Executive Committee
2015 Brown/Tufts Fogarty AIDS International Training and Research Program
- 2009 Member
Brown University Global Health Collaboratory Working Group

- 2016 Search Committee Member, Assistant Professor Research Scholar track, Department of Biostatistics/Center for Statistical Sciences, School of Public Health, Brown University
- 2016 Faculty Liaison; medical student exchange program, Alpert Medical School at Brown University and Technion Medical School, Israel
- 2017 Search Committee Member, Assistant Professor (Research), Department of Biostatistics/Center for Statistical Sciences, School of Public Health, Brown University

HOSPITAL COMMITTEES

- 2009 - Member, Israel Steering Committee
The Miriam Hospital

MANUSCRIPT REVIEWER

- 2004 - Antiviral Therapy
- 2005 - HIV Clinical Trials
- 2005 - Tropical Medicine and International Health
- 2006 - Lancet
- 2006 - PLOS Medicine
- 2006 - Journal of Biomedical Informatics
- 2006 - AIDS Research and Human Retroviruses
- 2007 - Journal of Infectious Diseases
- 2007 - Clinical Infectious Diseases
- 2007 - Journal of AIDS
- 2007 - Future Virology
- 2007 - Retrovirology
- 2007 - Journal of Medical Virology
- 2008 - Indian Journal of Medical Research
- 2009 - Journal of the International AIDS Society
- 2009 - AIDS
- 2009 - Expert Opinion On Drug Safety
- 2009 - FASEB

- 2010 - Medicinal Research Reviews
- 2010 - PLOS One
- 2010 - Journal of Computational Biology
- 2012 - Journal of Medical Microbiology and Diagnosis
- 2012 - Journal of Antimicrobial Chemotherapy
- 2014 - JAMA (Journal of the American Medical Association)
- 2014 - Antimicrobial Agents and Chemotherapy
- 2015 - European Journal of Clinical Microbiology & Infectious Diseases
- 2015 - AIDS Research and Therapy
- 2015 - Open Forum Infectious Diseases
- 2016 - Lancet HIV
- 2016 - Virulence

MEMBERSHIP IN SOCIETIES

- 1995 - Israel Medical Association
- 2000 - International AIDS Society
- 2005 - Infectious Diseases Society of America
- 2005 - HIV Medicine Association
- 2008 - American Academy of HIV Medicine
- 2013 - International Antiviral Society – USA
- 2015 - American Society of Microbiology

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. **R Kantor**, M Salai, A Ganel. Orthopedic long-term aspects of bladder extrophy. Clinical Orthopedics and Related Research, 1997; 335: 240-245. PMID 9020224.
2. **R Kantor**, A Barzilai, D Varon, U Martinowitz, J Gershoni. Prevalence of a CCR5 Gene 32-bp Deletion in an Israeli Cohort of HIV-1-Infected and Uninfected Hemophilia Patients. Journal of Human Virology 1998; 4: 299-301. PMID 10195255.
3. **R Kantor**, R Puzner, L Pali, Z Farfel. High alkaline phosphatase in subacute thyroiditis. Harefua 1999; 136: 599-602. PMID 10955064.
4. **R Kantor**, J Gershoni. Distribution of the CCR5 gene 32-Base Pair Deletion in Israeli Ethnic Groups. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1999; 20: 81-84. PMID 9928734.
5. **R Kantor**, H Mayan, N Reichert, Z Farfel. Kaposi's sarcoma post lung transplantation in a Sephardi Jewish woman. Dermatology 2000; 200: 49-50. PMID 10681615.

6. **R Kantor**, H Mayan, L Puritz, D Varon, Z Farfel. Acquired Hemophilia Masked by Warfarin Therapy. *Am J Med Sci* 2000;319: 197-201. PMID 10746834.
7. **R Kantor**, R Machakeno, M Gonzales, K Dupnik, J Schapiro, R W Shafer. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: An Expanded Data Model Integrating Natural Language Text and Sequence Analysis. *Nucleic Acids Research* 2001; 29: 296-299. PMID 11125118. PMC 29795.
8. H Mayan, **R Kantor**, U Rimon, N Golubev, Z Heyman, E Goshen, B Shalmon, P Weiss. Fatal liver infarction after transjugular intrahepatic portosystemic shunt procedure. *Liver* 2001; 21:361-4. PMID 11589774.
9. **R Kantor**, R Pazner, N Golubev, A Shinfeld, Z Farfel, A Smolinski. Ascending aortic pseudoaneurysm following coronary bypass in a hemodialysis patient with FUO. *Journal of Cardiovascular Surgery* 2001;42:633-4. PMID 11562590.
10. H Mayan, **R Kantor**, A Volner, Z Farfel. Acute respiratory failure with massive pulmonary infiltrates six weeks after coronary artery bypass operation. *Israel Medical Association Journal* 2001; 3: 67-68. PMID 11344810.
11. H Mayan, **R Kantor**, Z Farfel. The Trans Tubular Potassium Gradient in patients with drug-induced hyperkalemia. *Nephron* 2001; 89: 56-61. PMID 11528233.
12. **R Kantor**, JW Fessel, A Zolopa, D Israelski, N Shulman, J Montoya, M Harbour, J Schapiro, RW Shafer. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. *Antimicrobial Agents and Chemotherapy* 2002; 46:1086-92. PMID 11897594. PMC 127108.
13. **R Kantor**, L Zijenah, RW Shafer, S Mutetwa, E Johnston, R Lloyd, A von Lieven, D Israelski, D Katzenstein. HIV-1 subtype C reverse transcriptase and protease genotypes in patients from Zimbabwe failing antiretroviral therapy. *AIDS Research and Human Retroviruses* 2002; 18: 1407-13. PMID 12512512. PMC 2573400.
14. M Gonzales, TD Wu, J Taylor, I Belitskaya, **R Kantor**, D Israelski, S Chou, A Zolopa, WJ Fessel, RW Shafer. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. *AIDS* 2003; 17: 791-9. PMID 12660525. PMC 2573403.
15. TD Wu, CA Schiffer, M Gonzales, J Taylor, **R Kantor**, S Chou, D Israelski, A Zolopa, JW Fessel, RW Shafer. Mutation Patterns and Structural Correlates in HIV-1 Protease Following Varying Degrees of Protease Inhibitor Treatment. *Journal of Virology* 2003; 77: 4836-47. PMID 12663790. PMC 152121.
16. SY Rhee, MJ Gonzales, **R Kantor**, BJ Betts, J Ravela, RW Shafer. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. *Nucleic Acids Research* 2003; 31: 298-303. PMID 12520007. PMC 165547.
17. E Johnston, L Zijenah, S Mutetwa, **R Kantor**, C Kittinunvorakoon, D Katzenstein. High Frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C infected patients receiving antiretroviral treatment. *Journal of Virology* 2003; 77: 7682-7688. PMID 12805470. PMC 164829.
18. **R Kantor**, M Bakhanashvili, A Achiron. A mutated CCR5 gene in multiple sclerosis patients may have favorable prognostic implications in MS. *Neurology* 2003; 61: 238-240. PMID 12874407.
19. **R Kantor**, RW Shafer, S Follansbee, J Taylor, D Shilane, L Hurley, DP Nguyen, D Katzenstein, WJ Fessel. Evolution of drug resistance in HIV-1 among persons failing antiretroviral therapy. *AIDS* 2004;18:1503-11. PMID 15238768. PMC 2547474.
20. Akinsete, D Hirigoyen, C Cartwright, R Schut, **R Kantor**, K Henry. K103N mutation in antiretroviral therapy (ART) naïve African patients infected with HIV-1. *Clinical Infectious Diseases* 2004; 39:575-8. PMID 15356825.
21. **R Kantor**, RW Shafer, D Katzenstein for the HIV-1 Non-subtype B Workgroup. The HIV-1 Non-subtype B Workgroup: An International Collaboration for the Collection and Analysis of HIV-1 Non-subtype B Data. *Journal of the International AIDS Society* 2005;7:71. PMID 19825127. PMC 2740791.
22. P Balakrishnan, N Kumarasamy, **R Kantor**, S Solomon, S Vidya, KH.Mayer, M Newstein, SP Thyagarajan, D Katzenstein, B Ramratnam. HIV-1 genotypic variation in an antiretroviral

- treatment naïve population in South India. *Antiretroviral Research and Human Retroviruses* 2005; 21: 301-5. PMID 15943572.
23. **R Kantor**, D Katzenstein, B Efron, AP Carvalho, B Wynhoven, M Soares, P Cane, J Clarke, J Snoeck, C Pillay, S Sirivichayakul, K Ariyoshi, A Holguin, P Weidle, H Rudich, R Rodrigues, MB Bouzas, P Cahn, L Brigido, Z Grossman, V Soriano, W Sugiura, P Phanuphak, L Morris, AM Vandamme, J Weber, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro RW Shafer. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotypic evolution: results of a global collaboration. *PLOS Medicine* 2005; 2:e112. PMID 15839752. PMC 1087220.
 24. EJ Lee, **R Kantor**, L Zijenah, W Sheldon, P Mateta, E Johnston, J Wells, A Shetty, H Coovadia, Y Maldonado, SA Jones, C Contag, M Bassett, D Katzenstein. Breast-milk shedding of drug resistant subtype C HIV-1 among women receiving single dose nevirapine. *Journal of Infectious Diseases* 2005; 192:1260-4. PMID 16136470.
 25. J Snoeck, **R Kantor**, RW Shafer, K Van Laethem, K Deforche, AP Carvalho, B Wynhoven, MA Soares, P Cane, J Clarke, C Pillay, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, MB Bouzas, F Brun-Vézinet, C Reid, P Cahn, LF Brigido, Z Grossman, V Soriano, W Sugiura, P Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, RP Harrigan, R Camacho, JM Schapiro, D Katzenstein and AM Vandamme. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of the Human Immunodeficiency Virus are subtype dependent. *Antimicrobial Agents and Chemotherapy* 2006; 50:694-701. PMID 16436728. PMC 1366873.
 26. SY Rhee, **R Kantor**, D Katzenstein, R Camacho, L Morris, D Pillay, Z Grossman, P Phanuphak, P Cahn, V Soriano, LF Brigido, AM Vandamme, A Tanuri, J Weber, W Sugiura, JM Schapiro and RW Shafer. HIV-1 Pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. *AIDS* 2006;20:643-51. PMID 16514293. PMC 2551321.
 27. K Deforche, R Camacho, Z Grossman, T Silander, MA Soares, Y Moreau, RW Shafer, K Van Laethem, AP Carvalho, B Wynhoven, P Cane, J Snoeck, J Clarke, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, MB Bouzas, P Cahn, LF Brigido, V Soriano, W Sugiura, P Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, PR Harrigan, JM Shapiro, DA Katzenstein, **R Kantor**, AM Vandamme. Bayesian network analysis of resistance pathways against protease inhibitors. *Infection, Genetics and Evolution* 2007; 7:382-90. PMID 17127103.
 28. K Deforche, T Silander, R Camacho, Z Grossman, MA Soares, K Van Laethem, **R Kantor**, Y Moreau, AM Vandamme. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. *Bioinformatics*, 2006; 22:2975-9. PMID 17021157.
 29. S Kassaye, E Lee, **R Kantor**, E Johnston, M Winters, L Zijenah, P Mateta, D Katzenstein. Evolution of drug resistance in plasma and breast-milk after single-dose nevirapine in subtype C HIV-1: population clonal and sequencing analyses. *AIDS Research and Human Retroviruses* 2007;23:1055-61. PMID 17725424.
 30. K Deforche, RJ Camacho, Z Grossman, MA Soares, K Van Laethem, DA Katzenstein, PR Harrigan, **R Kantor**, R Shafer, AM Vandamme, on behalf of the non-B workgroup. Bayesian network analyses of resistance pathways against efavirenz and nevirapine. *AIDS* 2008; 22:2107-15. PMID 18832874. PMC 4788388.
 31. V Pillay, C Pillay, **R Kantor**, F Venter, L Levin, L Morris. HIV-1 subtype C drug resistance profiles among South African patients failing anti-retroviral therapy. *AIDS Research and Human Retroviruses* 2008;24:1449-54. PMID 19000027.
 32. PA Chan, SE Wakeman, T Flanigan, S Cu-Uvin, E Kojic, **R Kantor**. HIV-2 diagnosis and quantification in high-risk patients. *AIDS Research and Therapy* 2008;5:18. PMID 18700986. PMC 2529329.
 33. SG Kassaye, E Johnston, B McColgan, **R Kantor**, Lynn Zijenah, D Katzenstein. Envelope co-receptor tropism, drug resistance, and viral evolution among subtype C HIV-1 infected individuals receiving non-suppressive antiretroviral therapy. *JAIDS* 2009;50:9-18-22. PMID 19295330. PMC 2818215.
 34. D Bennett, R Camacho, D Otelea, D Kuritzkes, H Fleury, M Kiuchi, W Heneine, **R Kantor**, M Jordan, V Miller, J Schapiro, AM Vandamme, P Sandstrom, CAB Boucher, DVD Vijver, SY

- Rhee, T Liu, D Pillay, R Shafer. Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update. *PLOS One* 2009;4:e4724. PMID 19266092. PMC 2648874.
35. S Saravanan., M Vidya., P Balakrishnan, N Kumarasamy, SS Solomon, S Solomon, **R Kantor**, D Katzenstein, B Ramratnam, KH Mayer. Evaluation of Two Human Immunodeficiency Virus-1 Genotyping systems: the Viroseq™ 2.0 and an in house method. *Journal of Virological Methods* 2009; 159: 211-6. PMID 19490976. PMC 2923210.
 36. N Kumarasamy, V Madhavan, KK Venkatesh, S Saravanan, **R Kantor**, P Balakrishnan, B Devaleenal, S Poongulali, T Yeptommi, S Solomon, KH Mayer, C Benson, R Schooley. High Frequency of Clinically Significant Mutations after First Line Generic Highly Active Antiretroviral Therapy Failure: Implications for Second Line Options in Resource Limited Settings *Clinical Infectious Diseases* 2009; 49: 306-309. PMID 19522657.
 37. S Land, P Cunningham, J Zhou, K Frost, D Katzenstein, **R Kantor**, YMA Chen, S Oka, A DeLong, D Sayer, J Smith, EM Dax, M Law, TAQAS network Quality Assessment Scheme to Standardize the outcome of Asian Laboratories. TREAT Asia Quality Assessment Scheme (TAQAS) to Standardize the Outcome of HIV Genotypic Resistance Testing in a Group of Asian Laboratories. *Journal of Virological Methods* 2009;159:185-93. PMID 19490972, PMC 2863146.
 38. **R Kantor**, L Diero, A DeLong, L Kamle, S Muyonga, F Mambo, W Emonyi, P Chan, EJ Carter, J Hogan, N Buziba. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. *Clinical Infectious Diseases* 2009;49:454-62. PMID 19569972, PMC 4859427.
 39. M Vidya, S Saravanan, S Uma , N Kumarasamy, SS Solomon, S Solomon, **R Kantor**, D Katzenstein, B Ramratnam, KH Mayer , P Balakrishnan. Genotypic HIV-1 drug resistance among patients with immunologic failure to first-line antiretroviral therapy in south-India. *Antiviral Therapy* 2009;14:1005-9. PMID 19918105. PMC 3816397.
 40. Z El-Khatib, AK DeLong, D Katzenstein, AM Ekstrom, J Ledwaba, L Mohapi, F Laher, S Charalambous, A Karstaedt, M Petzold, L Morris, **R Kantor**. Drug resistance patterns and virus re-suppression among HIV-1 subtype C patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. *Journal of AIDS and Clinical Research* 2011;2:117-126. PMID 21927716. PMC 3174802.
 41. PA Chan, K Tashima, F Gillani, O Mintz, K Zeller, **R Kantor**. Transmitted Drug Resistance and Molecular Epidemiology in Antiretroviral Naïve HIV-1 Infected Patients Presenting to an Outpatient Clinic in Rhode Island. *AIDS Research and Human Retroviruses* 2011;7:275-81. PMID 20954831. PMC 3048815.
 42. A Huang, **R Kantor**, A DeLong, L Schreier, S Istrail. QColors: An Algorithm for Conservative Viral Quasispecies Reconstruction from Short and Non-Contiguous Next Generation Sequencing Reads. *Proceedings of Institute of Electrical and Electronics Engineers Conference on Bioinformatics and Biomedicine, Workshop on Computational Advances in Molecular Epidemiology* 2011;1:130-136.
 43. S Saravanan, V Madhavan, KG Murugavel, P Balakrishnan, SS Solomon, S Umapathy, **R Kantor**, N Kumarasamy, T Yeptommi, DM Smith, KH Mayer, S Solomon. The association between HIV-1 subtype C antiretroviral resistance and HLA prevalence in Southern India. *Journal of AIDS* 2011;57:e17-19. PMID 21775932. PMC 3154011.
 44. S Saravanan, M Vidya, P Balakrishnan, **R Kantor**, SS Solomon, D Katzenstein, N Kumarasamy, T Yeptommi, S Sivamalar, S Rifkin, KH Mayer, S Solomon. Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. *Clinical Infectious Diseases* 2012; 54: 995-1000. PMID 22323567. PMC 3571716.
 45. A DeLong, M Wu, D Bennett, N Parkin J Wu, J Hogan, **R Kantor**. Sequence Quality Analysis tool for HIV Type 1 Protease and Reverse Transcriptase sequence quality evaluation. *AIDS Research and Human Retroviruses* 2012;28:894-901. PMID 21916749. PMC 3399557.
 46. A Huang, J Hogan, S Istrail, A DeLong, D Katzenstein, **R Kantor**. Global Analysis of Sequence Diversity Within HIV-1 Subtypes Across Geographic Regions. *Future Virology* 2012;7:505-17. PMID 22822410. PMC 3400699.

47. S Saravanan, V Madhavan, SS Solomon, **R Kantor**, D Katzenstein, S Sivamalar, N Kumarasamy, DM Smith, KH Mayer, S Solomon, P Balakrishnan. Reverse Transcriptase Substitution at Codons 208 and 228 Among Treatment-experienced HIV-1 Subtype-C Infected Indian Patients Is Strongly Associated with Thymidine Analogue Mutations. *Journal of AIDS*, 2012;59:e26-7. PMID 22245718. PMC 3259528.
48. S Saravanan, M Vidya, **R Kantor**, S Sivamalar, S Gomathi, SS Solomon, N Kumarasamy, DM Smith, RT Schooley, S Solomon, P Balakrishnan. Unusual Insertion and Deletion at Codon 67 and 69 of HIV Type 1 Subtype C Reverse Transcriptase Among First-Line Highly Active Antiretroviral Treatment-Failing South Indian Patients: Association with Other Resistance Mutations. *AIDS Research and Human Retroviruses* 2012; 28:1763-5. PMID 22404052. PMC 3505055.
49. B Westley, AK DeLong, CS Tray, D Sophearin, EM Dufort, E Nerrienet, L Schreier, JI Harwell, **R Kantor**. Prediction of Treatment Failure using 2010 WHO Guidelines is Associated with High Misclassification Rates and Drug Resistance among HIV-Infected Cambodian Children. *Clinical Infectious Diseases*, 2012;55:432-440. PMID 22539664. PMC 3491779.
50. NE Alexander, PA Chan, T Rogo, Z Parillo, C Browning, B Isabell, C Calcione, S Chowdhury, P Simon, **R Kantor**. Interrupting Transmission of HIV and other Sexually Transmitted Infections in Rhode Island. *Medicine and Health RI* 2012;95:241-244. PMID 22970465. PMC 3770840.
51. PA Chan, A Huang, **R Kantor**. Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: Implications for pre-exposure prophylaxis. *Journal of the International AIDS Society* 2012;15:17701-5. PMID 23305651. PMC 3494163.
52. A Huang, **R Kantor**, A DeLong, L Schreier, S Istrail. QColors: An Algorithm for Conservative Viral Quasispecies Reconstruction from Short and Non-Contiguous Next Generation Sequencing Reads. *In Silico Biology* 2012;11:193-201. PMID 23202421. PMC 5530257.
53. A Jiamsakul, **R Kantor**, PCK Li, S Sirivichayakul, T Sirisanthana, P Kantipong, CKC Lee, A Kamarulzaman, W Ratanasuwan, R Ditangco, T Singtoroj, S Sungkanuparph. Comparison of Predicted Susceptibility between Genotype and Virtual Phenotype HIV Drug Resistance Interpretation Systems among Treatment-naive HIV-infected Patients in Asia: TASER-M Cohort Analysis. *BMC Research Notes* 2012;5:582-591. PMID 23095645. PMC 3505153.
54. S Saravanan, V Madhavan, P Balakrishnan, DM Smith, SS Solomon, S Sivamalar, S Poongulali, N Kumarasamy, RT Schooley, S Solomon, **R Kantor**. Darunavir is a good third-line antiretroviral agent for HIV-1 infected patients failing second-line protease inhibitor-based regimens in South India. *AIDS Research and Human Retroviruses* 2012;29:630-2. PMID 23045961. PMC 3581023.
55. PA Chan, S Kazi, A Rana, I Blazar, CC DeJong, KH Mayer, TK Huard, K Carleton, F Gillani, N Alexander, Z Parillo, TP Flanigan, **R Kantor**. New HIV infections at Southern New England academic institutions: Implications for prevention. *AIDS Research and Human Retroviruses* 2013;29:2013: 25-29. PMID 22724920. PMC 3537304.
56. KK Venkatesh, AK DeLong, **R Kantor**, S Chapman, J Ingersoll, J Kurpewski, MP De Pasquale, R D'Aquila, AM. Caliendo, S Cu-Uvin. Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load. *Journal of Women's Health* 2013;22:330-338. PMID 23531097. PMC 3627435.
57. S Sungkanuparph, A Jiamsakul, S Kiertiburanakul, S Sirivichayakul, J Praparattanapan, **R Kantor**; on behalf of the TREAT Asia Studies to Evaluate Resistance. Rilpivirine Resistance-Associated Mutations Among Antiretroviral-Naive Patients Infected With HIV-1 in Asia. *Journal of Acquired Immune Deficiency Syndromes* 2013; 62:98–100. PMID 23924642. PMC 3738917.
58. M Coetzer, B Westley, A DeLong, T Chhراing, S Dim, E Nerrienet, L Schreier, J Hogan, **R Kantor**. Extensive Drug Resistance in HIV-Infected Cambodian Children who are Undetected as Failing First-Line Antiretroviral Therapy by WHO 2010 Guidelines. *AIDS Research and Human Retroviruses* 2013;29:985-92. PMID 23506238. PMC 3685690.
59. K Morabito, **R Kantor**, L Schreier, A Tripathi. Detection of HIV-1 Minority Variants Containing the K103N Drug-Resistance Mutation Using a Simple Method to Amplify RNA Targets

- (SMART). *Journal of Molecular Diagnostics* 2013;15:401-12. PMID 23541840. PMC 3644729.
60. S Land, J Zhou, P Cunningham, A Sohn, T Singtoroj, D Katzenstein, M Mann, D Sayer, **R Kantor**. Capacity building and predictors of success for HIV drug resistance testing in the Asia Pacific Region and Africa. *Journal of the International AIDS Society* 2013;16:18580-18589. PMID 23845227. PMC 3709369.
 61. M Mann, L Diero, E Kemboi, F Mambo, W Injera, A DeLong, L Schreier, K Wools Kaloustian, N Buziba, **R Kantor**. Unplanned Antiretroviral Treatment Interruptions Induced by the Kenyan Post-Election Crisis are Associated with HIV virologic Failure. *Journal of AIDS* 2013;64:220-224. PMID 24047971. PMC 3920989.
 62. T Liu, JW Hogan, L Wang, S Zhang, **R Kantor**. Optimal allocation of gold standard testing under constrained availability: application to assessment of HIV treatment failure. *Journal of the American Statistical Association* 2013;108:1173-88. PMID 24672142. PMC 3963362.
 63. **R Kantor**, D Bettendorf, M Mann, RJ Bosch, D Katzenstein, S Cu-Uvin, R D'Aquila, L Frenkel, A Erice, S Fiscus, R Coombs for the ACTG A5077 Study Team. HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments from HIV-1–Infected Men and Women Enrolled in AIDS Clinical Trials Group Study A5077. *PLOS One* 2014;9:e393537. PMID 24699474. PMC 3974754.
 64. P Phanuphak, S Sirivichayakul, A Jiamsakul, S Sungkanuparph, N Kumarasamy, MP Lee, **R Kantor**, on behalf of the TASER-M Cohort. Transmitted Drug Resistance and Antiretroviral Treatment Outcomes in Non- Subtype B HIV1- Infected Patients in South East Asia. *Journal of AIDS* 2014;66:74-79. PMID 24413039. PMC 4074771.
 65. G Alemnji, P Fonjongo, T Peter, **R Kantor**, R Albalak, J Nkengasong. The Centrality of Laboratory Services in the Continuum of HIV Treatment and Prevention Cascade: need for effective linkages and referrals. *AIDS Patient Care and STDs* 2014;28:268-273. PMID 24742299. PMC 4826026.
 66. A Jiamsakul, S Sungkanuparph, M Law, **R Kantor**, J Preparattanapan, PCK Li, P Phanuphak, T Merati, W Ratanasuwan, C KC Lee, R Ditangco, M Mustafa, T Singtoroj, S Kiertiburanakul. HIV Multi-Drug Resistance at First-line Antiretroviral Failure and Subsequent Virological Response in Asia. *Journal of the International AIDS Society* 2014;17:19053. PMID 25141905. PMC 4139921.
 67. PA Chan, MB Reitsma, A DeLong, B Boucek, A Nunn, M Salemi, **R Kantor**. Phylogenetic and Geospatial Evaluation of HIV-1 Subtype Diversity at the Largest HIV Center in Rhode Island. *Infection Genetics and Evolution* 2014;28:358-66. PMID 24721515. PMC 4190103.
 68. **R Kantor**, A DeLong, M Balamane, L Schreier, RM Lloyd, W Injera, L Kamle, F Mambo, S Muyonga, D Katzenstein, J Hogan, N Buziba, L Diero. HIV Diversity and drug resistance from plasma and non-plasma analytes in a large treatment program in Western Kenya Genotyping. *Journal of the International AIDS Society* 2014;17:19262. PMID 25413893. PMC 4238965.
 69. S Sirivichayakul, **R Kantor**, AK DeLong, R Wongkunya, S Mekprasarn, K Ruxrungtham, AH Sohn, P Phanuphak. Transmitted HIV drug resistance at the Thai Red Cross Anonymous Clinic in Bangkok: Results from three consecutive years of annual surveillance. *Journal of Antimicrobial Chemotherapy* 2015; 70:1146-9. PMID 25525199. PMC: 4375389.
 70. T Rogo, AK DeLong, P Chan, **R Kantor**. Antiretroviral Treatment Failure, Drug resistance and Subtype Diversity in the only Pediatric HIV Clinic in Rhode Island. *Clinical Infectious Diseases* 2015;60:1426-35. PMID 25637585. PMC 4415056.
 71. **R Kantor**, L Smeaton, S Vardhanabhuti, SE Hudelson, CL Wallis, S Tripathi, MG Morgado, S Saravanan, P Balakrishnan, M Reitsma, K Braun, S Hart, J Mellors, E Halvas, J Hakim, T Flanigan, N Kumarasamy, TB Campbell, SH Eshleman, on behalf of the A5175 Study Team. Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated with Virologic Failure: Results from the Multi-national PEARLS (ACTG A5175) Clinical Trial. *Clinical Infectious Diseases* 2015;60:1541-9. NCT00084136. PMID 25681380. PMC 4425827.
 72. RA Oyomopito, YJ Chen, S Sungkanuparph, **R Kantor**, T Merati, WC Yam, T Sirisanthana, PCK Li, P Kantipong, P Phanuphak, CKC Lee, A Kamarulzaman, R Ditangco, SW Huang, AH Sohn, M Law, YMA Chen, on behalf of the TREAT Asia Studies to Evaluate Resistance

- (TASER). Risk group characteristics and viral transmission clusters in South-East Asian patients infected with HIV-1 circulating recombinant form (CRF)01_AE and subtype B. *Kaohsiung Journal of Medical Sciences* 2015;31:445-53. PMID 26362956. PMC 4929356.
73. PA Chan, A Huang, AK DeLong, JW Hogan, M Salemi, **R Kantor**. Phylogenetic investigation of a statewide HIV-1 epidemic reveals ongoing and active transmission networks among men who have sex with men. *Journal of AIDS* 2015;70:428-435. PMID 26258569. PMC 4624575.
 74. L Zhang, J Wang, M Coetzer, S Angione, A Tripathi, **R Kantor**. One step Ligation on RNA Amplification for the Detection of Point Mutations. *Journal of Molecular Diagnostics* 2015;17:679-88. PMID 26322949. PMC 4630173.
 75. SY Rhee, MR Jordan, E Raizes, A Chua, N Parkin, **R Kantor**, GU Van Zyl, I Mukui, MC Hosseinipour, L Frenkel, N Ndembi, RL Hamers, TF Rinke de Wit, CL Wallis, RK Gupta, J Fokam, C Zeh, JM Schapiro, S Carmona, D Katzenstein, M Tang, AF Aghokeng, T De Oliveira, AMJ Wensing, J Gallant, MA Wainberg, DD Richman, JE Fitzgibbon, M Schito, S Bertagnolio, C Yang, RW Shafer. HIV-1 Drug Resistance Mutations: Potential Application for Point-of-Care Genotypic Testing. *PLOS One* 2015;10:e0145772. PMID 26717411. PMC 4696791.
 76. KK Tee, **R Kantor**, S Sungkanuparph, Y Takebe, PL MBBS, R Ditangco, P Phanuphak, T Sirisanthana, B Sim, W Ratanasuwan, P Kantipong, A Kamarulzaman, on behalf of the TREAT Asia Studies to Evaluate Resistance – Monitoring (TASER-M) Database. Transmission networks of HIV-1 among men who have sex with men in east and southeast Asia. *Journal of AIDS* 2015;70:e28-30. PMID 25835606. PMC 4556551.
 77. K Brooks, A DeLong, M Balamane, L Schreier, M Orido, E Kemboi, M Chepkenja, E Kemboi, M D'Antuono, PA Chan, W Emonyi, L Diero, M Coetzer, **R Kantor**. HemaSpot™, a Novel Blood Storage Device for HIV Drug Resistance Testing. *Journal of Clinical Microbiology* 2016;54:223-5. PMID 26560534. PMC 4702722.
 78. PA Chan, C Towey, J Poceta, J Rose, T Bertrand, **R Kantor**, J Harvey, K Santamaria, N Alexander-Scott, A Nunn. Online hookup sites for meeting sexual partners among men who have sex with men in Rhode Island, 2013: A call for public health action. *Public Health Reports* 2016; 131: 264-71. PMID 26957661. PMC 4765975.
 79. A Huang, DA Katzenstein, S Saravanan, Y Wu, S Sirivichayakul, N Kumarasamy, F Zhang, P Phanuphak, **R Kantor**. Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes. *Open Forum Infectious Diseases* 2016;3:ofv158. PMID 27419147. PMC 4943563.
 80. K Brooks, L Diero, A DeLong, M Balamane, M Reitsma, E Kemboi, M Orido, M Coetzer, J Hogan, **R Kantor**. Treatment failure and drug resistance in HIV-positive Patients on Tenofovir-Based First-Line Antiretroviral Therapy in western Kenya. *Journal of International AIDS Society* 2016;19:20798. PMID 27231099. PMC 4882399.
 81. J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee, VC Marconi, L Diero, K Brooks, K Theys, TF Rinke de Wit, M Arruda, F Garcia, S Monge, HF Günthard, CJ Hoffmann, PJ Kanki, N Kumarasamy, B Kerschberger, O Mor, C Charpentier, E Todesco, C Roxk, L Gras, EK Halvas, H Sunpath, D Di Carlo, A Antinori, M Andreoni, A Latini, C Mussini, A Aghokeng, A Sonnerborg, U Neogi, WJ Fessel, S Agolory, C Yang, JL Blanco, JM Juma, E Smit, D Schmidt, C Watera, J Asio, W Kirungi, A Tostevin, T El-Hay, N Clumeck, D Goedhals, C van Vuuren, PA Bester, C Sabin, I Mukui, MM Santoro, CF Perno, G Hunt, L Morris, R Camacho, T de Oliveira, D Pillay, E Schulter, A Murakami-Ogasawara, G Reyes-Terán, K Romero, S Avila-Rios, S Sirivichayakul, K Ruxrungtham, S Mekprasan, D Dunn, P Kaleebu, E Raizes, **R Kantor**, RW Shafer, RK Gupta. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. *Lancet Infectious Diseases* 2016;16: 565–75. PMID 26831472. PMC 4835583.
 82. E Dufort, W Nyandiko, A DeLong, K Wools-Kaloustian, S Ayaya, J Harwell, **R Kantor**. Misclassification of Treatment Failure Using Immunologic and Clinical Monitoring in HIV Infected Children and Adolescents in Western Kenya. *Journal of the Pediatric Infectious Diseases Society* 2017;6:285-88. PMID 27130578.
 83. J Gregson, P Kaleebu, V Marconi, C van Vuuren, N Ndembi, R Hamers, P Kanki, C Hoffmann, S Lockman, D Pillay, T de Oliveira, N Clumeck, G Hunt, B Kerschberger, R Shafer, C Yang, E Raizes, **R Kantor**, RK Gupta. Occult drug resistance to thymidine

- analogues and multidrug resistant HIV-1 following failure of first line tenofovir combined with cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multicenter cohort study. *Lancet Infectious Diseases* 2017;17:296-304. PMID 27914856. PMC 5421555.
84. S Saravanan, B Kausalya, S Gomathi, S Sivamalar, B Pachamuthu, P Selvamuthu, A Pradeep, S Sunil, SN Mothi, DM Smith, **R Kantor**. Etravirine and Rilpivirine drug resistance among HIV-1 subtype C infected Children failing non -nucleoside reverse transcriptase inhibitor-based regimens in South India. *AIDS Research in Human Retroviruses* 201;33:567-74. PMID 27869478. PMC 5695734.
 85. T Liu, JW Hogan, M Daniels, M Coetzer, Y Xu, G Bove, AK Delong, L Ledingham, M Orido, L Diero, **R Kantor**. Improved HIV-1 Viral Load Monitoring Capacity Using Pooled Testing with Maker-Assisted Deconvolution. *Journal of AIDS* 2017;75:580-87. PMID 28489730. PMC 5503773.
 86. R Paredes, P Tzou; G van Zyl, G Barrow, R Camacho, S Carmona, P Grant, R Gupta, R Hamers, PR Harrigan, M Jordan, **R Kantor**, DA Katzenstein, DR Kuritzkes, F Maldarelli, D Otelea, CL Wallis, JM Schapiro, RW Shafer. Collaborative Update of a Rule-Based Expert System for HIV-1 Genotypic Resistance Test Interpretation. *PLOS One* 2017;12:e0181357. PMID 28753637. PMC 5533429.
 87. SY Rhee, V Varghese, SP Holmes, G Van Zyl, K Steegen, MA Boyd, DA Cooper, S Nsanzimana, S Saravanan, C Charpentier, T de Oliveira, MA Etiebet, F Garcia, D Goedhals, P Gomes, HF Günthard, RL Hamers, CJ Hoffmann, G Hunt, A Jiamsakul, P Kaleebu, P Kanki, **R Kantor**, B Kerschberger, VC Marconi, J Ndahimana, N Ndembi, N Ngo-Giang-Huong, C Rokx, MM Santoro, JM Schapiro, D Schmidt, L Seu, KC Sigaloff, S Sirivichayakul, L Skhosana, H Sunpath, M Tang, C Yang, S Carmona, RK Gupta, RW Shafer. Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration. *EBioMedicine* 2017;18: 225-35. PMID 28365230. PMC 5405160.
 88. HA Duarte, N Panpradist, IA Beck, B Lutz, J Lai, R Kanthula, **R Kantor**, A Tripathi, S Saravanan, I MacLeod, MH Chung, G Zhang, C Yang, LM Frenkel. Current status of point-of-care testing for HIV drug resistance. *Journal of Infectious Diseases* 2017;216(suppl 9):S824-S828. PMID 29040621.
 89. C Godfrey, M Bobkova, C Boucher, G Ravasi, P Chen, F Zhang, Y Wu, **R Kantor**. Regional challenges in HIV drug resistance. *Journal of Infectious Diseases* 2017;216(suppl 9):S816-S819. PMID 28968824. PMC 5853282.
 90. M Coetzer, L Ledingham, L Diero, E Kemboi, M Orido, **R Kantor**. *Gp41* and *Gag* amino acids linked to HIV-1 Protease Inhibitor Based 2nd-line Failure in HIV-1 subtype A from Western Kenya. *Journal of the International AIDS Society* 2017;20: 20:e25024. PMID 29098809. PMC 5810327.
 91. S Saravanan, S Gomathi, S Sivamalar, B Kausalya, P Selvamuthu, K Brooks, N Kumarasamy, P Balakrishnan, SS Solomon, S Solomon, S Cu-Uvin, **R Kantor**. High Discordance in Blood and Genital Tract HIV-1 Drug Resistance in Indian Women Failing 1st-Line Therapy. *Journal of Antimicrobial Chemotherapy* 2018;73:2152-2161. PMID 29800305
 92. R Reece, M D'Antuono, A Delong, K Tashima, **R Kantor**. Pre-switch Resistance to Complera and Stribild and its Impact on HIV Virological Outcome. *Journal of Clinical Virology* 2018;105:11-17.
 93. **R Kantor**, A DeLong, L Schreier, M Reitsma, E Kemboi, M Orido, S Obonge, R Boinett, M Rono, W Emonyi, N Buziba, L Diero. Second-Line Treatment Failure, Drug Resistance and Resistance Accumulation among HIV-Infected Patients in a Large Treatment Program in Western Kenya (in press, *AIDS*).
 94. P Chan, MC Montgomery, J Rose, A Tributino, C Crowley, MM Medina, R Patel, K Mayer, **R Kantor**, AS Nunn. Statewide Evaluation of New HIV Diagnoses in Rhode Island: Implications for Prevention. *Public Health Rep.* 2018 [Epub ahead of print].

OTHER PEER-REVIEWED PUBLICATIONS

1. **R Kantor**, J Gershoni. CCR5 - The HIV Coreceptor Now In Israel. Harefua 1999; 137:405-409. PMID 11419046.
2. **R Kantor**, H Mayan, D Varon. Acquired Hemophilia. Harefua, 2000; 138: 860-4. PMID 10883255.
3. RW Shafer, **R Kantor**, M Gonzales. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Reviews 2000; 2: 211-228. PMC 2604813.
4. **R Kantor**, D Katzenstein. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Reviews 2003; 5: 25-35. PMID 12875105.
5. M Peleg, **R Kantor**. Approaches for guideline versioning using GLIF. AMIA Annual Symposium Proceedings. 2003:509-13. PMID 14728225. PMC 1480025.
6. **R Kantor**, D Katzenstein. Drug resistance in non-subtype B HIV-1. Journal of Clinical Virology 2004;29:152-9. PMID 14962783.
7. **R Kantor**. Impact of HIV-1 *pol* diversity on drug resistance and its clinical implications. Current Opinion in Infectious Diseases 2006;19:594-606. PMID 17075337.
8. **R Kantor**, J Gershoni. HIV/AIDS and the Genetic Revolution - Custom Tailoring Antiretroviral Regimens in the Management of HIV. The International Journal for Healthcare Technology and Management 2007;7:478-491.
9. PA Chan, **R Kantor**. Transmitted Drug Resistance in Non-subtype B HIV-1 Infection. HIV Therapy 2009;3:447-465. PMID 20161523. PMC 2800377.
10. M Mann, MN Lurie, S Kimaiyo, **R Kantor**. Effects of Political Conflict-Induced Treatment Interruptions on HIV Drug Resistance. AIDS Reviews 2013;15:15-24, 2013. PMID 23449225. PMC 3774601.
11. **Kantor R**. Research Components of the Brown Kenya Program: A Personal and Professional Perspective. RI Medical Journal 2013;96:16-19. PMID 24087816.

BOOKS AND BOOK CHAPTERS

1. P Chan, **R Kantor**. Enfuvirtide: Update on recent recommendations and clinical guidelines. <http://www.antimicrobe.org> 2010.
2. R. Gulick, P. Chan, **R Kantor**. Vicriviroc. <http://www.antimicrobe.org> 2008.
3. P. Chan, **R Kantor**. Enfuvirtide. <http://www.antimicrobe.org> 2008.
4. **R Kantor**, K Tashima. Treatment experienced patients. In: HIV Clinical Manual, 2nd Edition. Editors: Nina Singh, Robert W. Shafer, Susan Swindells. 2005; updated 2006, 2008.
5. **R Kantor**, G Morse. GP41 inhibitors – enfuvirtide and other fusion inhibitors. In: Antimicrobial Therapy and Vaccines, Volume II: Antimicrobial Agents, 2003, pages 747-756. Editors: Victor L. Yu, Geoffrey Edwards, Peggy S. McKinnon, Charles Peloquin, Gene D. Morse (Apple Trees Productions, LLC).
6. **R Kantor**, Ethan Rubinstein. Antibiotics: a guide for the educated user. Prolog Publications. Israel 2001.

PUBLICATIONS SUBMITTED OR IN PREPARATION

1. Y Xu, T Liu, MJ Daniels, **R Kantor**, A Mwangi, JW Hogan. Classification using Ensemble Learning under Weighted Misclassification Loss (under review, Statistics in Medicine).
2. R Ramirez, A Olson, R Tandon, B Matuszek, J Morgan, **R Kantor**, M Sagar, A Henderson, G Skowron, G Sahu. Simple Viral Outgrowth Assay Identifies Effector Memory CD4+ T cells as a Major Cell Subset Harboring Clonal Inducible Replication-competent Latent HIV-1 in a Patient on Long-term Antiretroviral Therapy (under review, Virology).
3. M Howison, M Coetzer, **R Kantor**. Measurement error and variant-calling in deep Illumina sequencing of HIV (under revision, Bioinformatics).

4. H Ji, E Enns, CJ Brumme, N Parkin, M Howison, ER Lee, R Capina, E Marinier, S Avila Rios, P Sandstrom, G Van Domselaar, R Harrigan, R Paredes, **R Kantor**, M Noguera-Julian. Bioinformatic data processing pipelines in support of next generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus (Under review, JIAS).
5. **R Kantor**, S Vardhanabhuti, S Tripathy, MG Morgado, S Saravanan, CL Wallis, S Hudelson, SH Eshleman, T Campbell on behalf of the A5175 Study Investigators. Association between baseline and failure HIV drug resistance in the ACTG PEARLS study (in preparation).
6. K Sagoe, M Balamane, M Reitsma, M Coetzer, M D'antuono, M Lartey, **R Kantor**. HIV treatment failure and drug resistance after one, two and three years of first-line antiretroviral therapy in Ghana (in preparation).
7. M Coetzer, L Ledingham, L Diero, E Kemboi, M Orido, W Emonyi, **R Kantor**. Longitudinal Evaluation of Coreceptor Use in Human Immunodeficiency Virus 1 Subtype A in Western Kenya (in preparation).
8. A Guang, M Howison, M Coetzer, L Ledingham, M D'Antuono, PA Chan, C Lawrence, CW Dunn, **R Kantor**. Preserving intra-patient variance improves phylogenetic
9. inference of HIV transmission networks (in preparation).

ABSTRACTS

1. **R Kantor**, M Salai, A Ganel. Orthopedic long term aspects of bladder extrophy. Bi-national Argentina-Israel orthopedic meeting; December 5, 1994; Jerusalem, Israel.
2. M Salai, **R Kantor**, A Ganel. Orthopedic long term aspects of bladder extrophy. European orthopedic and traumatology convention (EFORT); July 4-7, 1995; Munich, Germany.
3. **R Kantor**, J Gershoni. CCR5 and genetic resistance to HIV in Jews. Genomic views on Jewish history; May 31-June 2, 1999; Ma'ale-Hachamisha, Israel.
4. M Bakhanashvili, **R Kantor**, G Ishuev, I Zeitun, E Novipsky, S Miron, A Achiron. Expression of CCR5 mutation in patients with multiple sclerosis. 11th Meeting of the European Neurological Society, April 21-25, 2001; Paris, France.
5. **R Kantor**, AR Zolopa, D Israelski, N Shulman, J Montoya, M Harbour, WJ Fessel, RW Shafer. Evolution of IAS-USA primary protease resistance mutations during protease inhibitor salvage therapy. 5th International Workshop on HIV Drug Resistance & Treatment Strategies, June 4-8, 2001; Scottsdale, Arizona, USA.
6. E Johnston, S Mutetwa, L Zijenah, A von Lieven, D Israelski, C Kittinunvorakoon, **R Kantor**, D Katzenstein. Presence of CXCR4-Tropic Viruses among Subtype C HIV-Infected Individuals. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002; Seattle, Washington, USA.
7. **R Kantor**, R Shafer, D Katzenstein, S Follansbee, WJ Fessel. Evolution of reverse transcriptase and protease resistance mutations in HIV-1-infected patients on antiretroviral therapy. 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002; Seattle, Washington, USA.
8. **R Kantor**, R Lloyd, RW Shafer, E Johnston, L Guay, JB Jackson, SH Eshleman, D Katzenstein. Comparison of Mother-to-Child Transmission (MTCT) and Genotypic Resistance in HIV-1 Subtypes A, C, and D after Single Dose Nevirapine (sd-NVP) in Africa. 9th Conference on Retroviruses and Opportunistic Infections, February 24-48, 2002; Seattle, Washington, USA.
9. **R Kantor**, D Katzenstein, S Sirivichayakul, P Cane, C Pillay, J Snoeck, Z Grossman, AM Vandamme, L Morris, D Pillay, P Phanuphak, J Schapiro, RW Shafer. Classical subtype B resistance mutations and novel candidate non-subtype B HIV-1 isolates. 14th International AIDS Conference, July 7-12, 2002; Barcelona, Spain.
10. **R Kantor**, D Katzenstein, M Gonzales, S Sirivichayakul, P Cane, C Pillay, J Snoeck, Z Grossman, AM Vandamme, L Morris, D Pillay, P Phanuphak, J Schapiro, R Shafer. Influence of subtype and treatment on genetic profiles of HIV-1 RT and protease: Do they act independently in predicting position-specific mutation probabilities in non-subtype B sequences? 11th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, July 2-5, 2002; Seville, Spain.

11. **R Kantor**, L Zijenah, RW Shafer, S Mutetwa, E Johnston, R Lloyd, A von Lieven, D Israelski, D Katzenstein. HIV-1 subtype C reverse transcriptase and protease genotypes in patients from Zimbabwe failing antiretroviral therapy. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002; San-Diego, California, USA.
12. **R Kantor**, D Katzenstein, M Gonzales, A Carvalho, B Wynhoven, M Soares, P Cane, J Snoeck, S Sirivichayakul, K Ariyoshi, A Holguin, C Pillay, Z Grossman, R Rodrigues, M Bouzas, P Cahn, L Brigido, L Morris, V Soriano, W Sugiura, P Phanuphak, AM Vandamme, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro, RW Shafer. Genotypic analyses of RT and protease sequences from persons infected with non- subtype B HIV-1. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston, Massachusetts, USA.
13. E Lee, **R Kantor**, E Johnston, P Mateta, L Zijenah, D Katzenstein. Breast milk shedding of drug resistant subtype C HIV-1 and among women receiving single dose Nevirapine. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston, Massachusetts, USA.
14. S Hart, RW Shafer, A Tanuri, M Soares, F Brun-Vezinet, Z Grossman, H Rudich, D Ram, N Richards, P Mugenyi, E Arts, L Palmisano, S Vella, A De Felici, **R Kantor**. Global mapping of HIV-1 drug resistance patterns. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003; Boston, Massachusetts, USA.
15. **R Kantor**, A Carvalho, B Wynhoven, M Soares, P Cane, J Snoeck, S Sirivichayakul, K Ariyoshi, A Holguin, C Pillay, Z Grossman, R Rodrigues, M Bouzas, P Cahn, L Brigido, L Morris, V Soriano, W Sugiura, P Phanuphak, AM Vandamme, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro, RW Shafer, D Katzenstein. Nucleic Acid Differences between HIV-1 non-B and B Reverse Transcriptase and Protease Sequences at Drug Resistance Positions. 12th International HIV drug resistance workshop, June 10-14, 2003; Los Cabos, Mexico.
16. **R Kantor**, E Lee, E Johnston, P Mateta, L Zijenah, Y Maldonado, D Katzenstein for the HPTN 023 Study Team. Rapid flux in NNRTI resistance mutations detected in subtype C HIV-1 infected women receiving single dose NVP. 12th International HIV drug resistance workshop, June 10-14, 2003; Los Cabos, Mexico.
17. J Snoeck, **R Kantor**, R Shafer, I Derdelinckx, A Carvalho, B Wynhoven, M Soares, P Cane, S Sirivichayakul, K Ariyoshi, A Holguin, C Pillay, Z Grossman, R Rodrigues, M Bouzas, P Cahn, L Brigido, L Morris, V Soriano, W Sugiura, P Phanuphak, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro, D Katzenstein, AM Vandamme. Comparison of five interpretation algorithms for the prediction of protease inhibitor susceptibility in HIV-1 non-B subtypes. 12th International HIV drug resistance workshop, June 10-14, 2003; Los Cabos, Mexico.
18. C Pillay, M Ntsala, **R Kantor**, C Chezzi, F Venter, L Levin, L Morris. HIV-1 subtype C drug resistance profiles among South African patients failing anti-retroviral therapy. The 2nd IAS conference on HIV pathogenesis and treatment, July 13-16, 2003; Paris, France.
19. O Akinsete, C Cartwright, R Schut, **R Kantor**, K Henry. K103N mutation in antiretroviral therapy (ART) naïve African patients infected with HIV-1. The 41st Annual Meeting of IDSA 2003; October 9-12, 2003; San-Diego, CA, USA.
20. **R Kantor**, RW Shafer, B Efron, A Carvalho, B Wynhoven, M Soares, P Cane, J Snoeck, S Sirivichayakul, K Ariyoshi, A Holguin, C Pillay, Z Grossman, R Rodrigues, M Bouzas, P Cahn, L Brigido, L Morris, V Soriano, W Sugiura, P Phanuphak, AM Vandamme, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro, D Katzenstein. HIV-1 Subtype-Related Differences in Genotypic Evolution: Analysis of Subtypes B and C Reverse Transcriptase (RT) and Protease Sequences. 11th Conference on Retroviruses and Opportunistic Infections, February 8-12, 2004; San Francisco, California, USA.
21. E Johnston, M Ketunuti, **R Kantor**, D Bhattacharaya, L Zijenah, D Katzenstein. Persistence of X4-tropic Virus Despite Antiretroviral Treatment in Subtype C HIV. 11th Conference on Retroviruses and Opportunistic Infections, February 8-12, 2004; San Francisco, California, USA.
22. J Snoeck, **R Kantor**, RW Shafer, K Van Laethem, K Deforche, A Carvalho, B Wynhoven, M Soares, P Cane, J Clarke, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, M Bouzas, F Brun-Vézinet, C Reid, P Cahn, L Brigido, Z Grossman, V Soriano, W Sugiura, P

- Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro, D Katzenstein, AM Vandamme. Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors are Subtype Dependent.. 13th International HIV drug resistance workshop, June 8-12, 2004; Tenerife Sur, Canary Islands, Spain.
23. **R Kantor**, D Katzenstein, SY Rhee, A Carvalho, B Wynhoven, M Soares, P Cane, J Snoeck, S Sirivichayakul, K Ariyoshi, A Holguin, C Pillay, Z Grossman, R Rodrigues, M Bouzas, P Cahn, L Brigido, L Morris, V Soriano, W Sugiura, P Phanuphak, AM Vandamme, D Pillay, A Tanuri, R Harrigan, R Camacho, J Schapiro, RW Shafer. HIV-1 protease and RT mutations according to subtype and antiretroviral therapy: A watch list for epidemiologic studies using a web-based application. 15th International AIDS Conference, July 12-16, 2004; Bangkok, Thailand.
 24. P Balakrishnan, N Kumarasamy, S Solomon, S Vidya, **R Kantor**, RW Shafer, T Flanigan, KH Mayer, D Boden, D Katzenstein, B Ramratnam. Protease and reverse transcriptase mutations at drug resistance positions in untreated hiv-1 clade C infected southern Indian patients. 15th International AIDS Conference, July 12-16, 2004; Bangkok, Thailand.
 25. K Deforche, R Camacho, Z Grossman, MA Soares, RW Shafer, K Van Laethem, AP Carvalho, B Wynhoven, P Cane, J Clarke, C Pillay, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, MB Bouzas, F Brun-Vézinet, C Reid, P Cahn, LF Brigido, V Soriano, W Sugiura, P Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, PR Harrigan, JM Schapiro, D Katzenstein, **R Kantor**, AM Vandamme. Applying Bayesian networks to study nelfinavir resistance pathways in subtypes A, B, C, F and G. 3rd European HIV Drug Resistance Workshop, 30 March-1 April, 2005; Athens, Greece.
 26. E Lee, **R Kantor**, E Johnston, S Kassaye, L Zijenah, D Katzenstein. Clonal Analysis of Drug-resistant Mutations in Plasma and Breast Milk following Single-dose Nevirapine. 12th Conference on Retroviruses and Opportunistic Infections, February 22-26, 2005; Boston, Massachusetts, USA.
 27. SY Rhee, **R Kantor**, RW Shafer. The effect of population stratification on identifying antiretroviral drug selection and genetic drift in cross-sectional studies. The International workshop for HIV dynamics and evolution, April 23-36, 2005; Cleveland, Ohio, USA.
 28. **R Kantor**, A DeLong, RW Shafer, AP Carvalho, B Wynhoven, P Cane, S Sirivichayakul, M A Soares, J Snoeck, H Rudich, R Rodrigues, A Holguin, K Ariyoshi, MB Bouzas, P Cahn, W Sugiura, V Soriano, LF Brigido, Z Grossman, L Morris, AM Vandamme, A Tanuri, P Phanuphak, J Weber, D Pillay, PR Harrigan, R Camacho, JM Schapiro, J Hogan, DA Katzenstein. Selection of resistance following first-line antiretroviral regimens among HIV-1 subtypes. 14th International HIV drug resistance workshop, June 7-11, 2005; Quebec City, Canada.
 29. K Deforche, R Camacho, Z Grossman, T Silander, MA Soares, RW Shafer, K Van Laethem, AP Carvalho, B Wynhoven, P Cane, J Clarke, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, MB Bouzas, F Brun-Vézinet, P Cahn, LF Brigido, V Soriano, W Sugiura, P Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, PR Harrigan, JM Schapiro, D Katzenstein, **R Kantor**, AM Vandamme. Using bayesian networks for HIV-1 pol sequences of various subtypes to map nevirapine and efavirenz resistance. 14th International HIV drug resistance workshop, June 7-11, 2005; Quebec City, Canada.
 30. K Deforche, R Camacho, Z Grossman, T Silander, MA Soares, RW Shafer, K Van Laethem, AP Carvalho, B Wynhoven, P Cane, J Clarke, S Sirivichayakul, K Ariyoshi, A Holguin, H Rudich, R Rodrigues, MB Bouzas, F Brun-Vézinet, P Cahn, LF Brigido, V Soriano, W Sugiura, P Phanuphak, L Morris, J Weber, D Pillay, A Tanuri, PR Harrigan, JM Schapiro, D Katzenstein, **R Kantor**, AM Vandamme. Interactions between nevirapine resistance mutations and NRTI resistance mutations and NRTI resistance mutations. 14th International HIV drug resistance workshop, June 7-11, 2005; Quebec City, Canada.
 31. **R Kantor**, J Weltman. Informational Entropy of HIV-1 Protease in Sequences From Treated and Untreated Persons Infected With Multiple HIV-1 Subtypes. Lifespan 13th Annual Hospital Research Celebration. Rhode Island Hospital, September 29, 2005
 32. D Katzenstein, M Winters, S Fiscus, **R Kantor**, D Bettendorf, RJ Bosch, M Cooper, S Cu-Uvin, R D'Aquila, EA Luque, W Cavert, L Frenkel, N Ellis, R Coombs for the ACTG A5077

- Study Team. Drug resistance in plasma and genital compartments among viremic, multi-drug experienced men and women. 13th Conference on Retroviruses and Opportunistic Infections, February 5-9, 2006; Denver, Colorado, USA.
33. M Vidya, B Ramratnam, P Balakrishnan, N Kumarasamy, S Solomon, KH Mayer, T Flanigan, D Katzenstein, **R Kantor**. Comparison of HIV-1 subtype C protease and RT sequences from Southern India and Zimbabwe. The National Conference of Research In HIV & AIDS, April 21-23, 2006, Delhi, India.
 34. N Kumarasamy, V Madhavan, K Venkatesh, S Saravanan, **R Kantor**, P Balakrishnan, B Devaleenol, S Solomon, K Mayer, R Schooley. The high frequency of clinically significant mutations following first-line generic HAART failure: Implications for second-line options in resource-limited settings. 15th Conference on Retroviruses and Opportunistic Infections, February 3-8, 2008; Boston, MA.
 35. **R Kantor**, M. Wantman, D. Katzenstein, D. Bettendorf, R.J. Bosch, S. Fiscus, R. D'Aquila, L.M. Frenkel, R. Coombs for the ACTG A5077 Study Team. Viral shedding and drug resistance in plasma and genital compartments among viremic, multi-drug experienced HIV-infected men and women. 15th Conference on Retroviruses and Opportunistic Infections, February 3-8, 2008; Boston, MA.
 36. **R Kantor**, L Diero, A DeLong, L Kamle, E Walumbe, S Muyonga, F Mambo, W Imonyi, P Chan, JE. Carter, N Buziba. Immunological monitoring as an indicator of virological failure may lead to premature switch to second line HAART regimens. 15th Conference on Retroviruses and Opportunistic Infections, February 3-8, 2008; Boston, MA.
 37. M Vidya, S Saravanan, N Kumarasamy, S Uma, SS Solomon, S Solomon, D Katzenstein, KH Mayer, B Ramratnam, **R Kantor**, P Balakrishnan. Thymidine analogue reverse transcriptase resistance mutation patterns observed in the context of treatment failure in South Indian HIV-1 infected patients. 17th International AIDS Conference, August 3-8, 2008; Mexico City, Mexico.
 38. M Vidya, S Saravanan, N Kumarasamy, **R Kantor**, S Solomon, B Ramratnam, S Solomon, K Mayer, D Katzenstein, P Balakrishnan. Antagonism between subtype C HIV-1 Reverse-Transcriptase Mutation K65R and TAMs among Tenofovir naïve patients. 17th International AIDS Conference, August 3-8, 2008; Mexico City, Mexico.
 39. S Saravanan, M Vidya, P Balakrishnan, **R Kantor**, B Ramratnam, S Solomon, S Solomon, KH Mayer, D Katzenstein, N Kumarasamy. Unusual insertion and deletion in the beta3-beta4 finger subdomain of HIV-1 subtype C reverse transcriptase from HAART failing South Indian patients: incidence and association with other resistance mutations. 17th International AIDS Conference, August 3-8, 2008; Mexico City, Mexico.
 40. S Land, P Cunningham, J Zhou, K Frost, D Katzenstein, **R Kantor**, A DeLong, D Sayer, J Smith, EM Dax, M Law. A Quality Assessment Scheme to Standardize the Outcome of HIV Genotypic Resistance Testing in a Group of Asian Laboratories. 17th International AIDS Conference, August 3-8, 2008; Mexico City, Mexico.
 41. D Bennett, D Pillay, V Miller, **R Kantor**, J Schapiro, DVD Vijver, AM Vandamme, R Camacho, M Jordan, R Shafer and WHO Surveillance Mutations List Working Group. The WHO updated list of mutations for surveillance of transmitted drug-resistant HIV. 16th Conference on Retroviruses and Opportunistic Infections, February 7-11, 2009; Boston, Massachusetts, USA.
 42. A Kamau, C Seebregts, D Katzenstein, **R Kantor**, S Cassol, L Morris, C Hoffman, T de Oliveira. Itemset mining: An approach to identify co-occurrence of drug resistance mutations among HIV-1-infected patients failing therapy. 18th International HIV Drug Resistance Workshop, June 9-13, 2009; Fort Myers, Florida, USA.
 43. **R Kantor**, A DeLong, J Ledwaba, A Kamau, C Seebregts, T de Oliveira, J Hogan, N Martinson, J McIntyre, L Morris, and D Katzenstein. Association Between Mutations Affects Drug Resistance Selection by Single-dose Nevirapine in HIV-1 Subtype C. 18th International HIV Drug Resistance Workshop, June 9-13, 2009; Florida, USA.
 44. **R Kantor**, L Diero, A DeLong, M Balamane, RM Lloyd, W Injera, L Kamle, F Mambo, S Muyonga, L Watetu, EJ Carter, D Katzenstein, J Hogan, N Buziba. HIV Diversity and Drug Resistance in Western Kenya from Plasma and non-Plasma Genotyping. 18th International HIV Drug Resistance Workshop, June 9-13, 2009; Florida, USA.

45. EH Geng, K Wools-Kaloustian, A Siika, B Musick, L Diero, **R Kantor**, J Hogan, SG Deeks, C Yiannoutsos, JN Martin. The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery Network in Africa. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July, 2009; Cape Town, South Africa.
46. S Saravanan, M Vidya, S Uma, N Kumarasamy, D Smith, B Ramratnam, S Solomon, K Mayer, D Katzenstein, P Balakrishnan, **R Kantor**. HIV-1 RT nucleotide substitutions among subtype C infected patients in South India. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009; Cape Town, South Africa.
47. S Saravanan, M Vidya, SS Solomon, N Kumarasamy, **R Kantor**, B Ramratnam, S Solomon, K Mayer, D Katzenstein, P Balakrishnan. Polymorphisms in RT codons 208 and 228 among treatment-experienced HIV-1 subtype C infected Indian patients is strongly associated with thymidine analogue mutations (TAMs). 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, July 19-22, 2009; Cape Town, South Africa.
48. S Saravanan, V Madhavan, P Balakrishnan, SS Solomon, **R Kantor**, D Katzenstein, B Ramratnam, S Solomon, KH Mayer, N Kumarasamy. High Frequency of Protease Drug Resistance Mutation among HIV-1 Infected Patients Exposed to Second-line Antiretroviral Regimen in South India. 17th Conference on Retroviruses and Opportunistic Infections, February 16-20, 2010; San Francisco, CA.
49. M. Holodniy, RS Diaz, RL Mathis, PM Feorino, C Loveday, Z Grossman, **R Kantor** YW Tang, RM Lloyd. Detection of mixtures of Hepatitis C virus (HCV) types. International Liver Congress 2010 – the 45th annual meeting of the European Association for the Study of the Liver (EASL). April 14-18, 2010; Vienna, Austria.
50. A Huang, J Hogan, S Istrail, A DeLong, **R Kantor**. Stratification by HIV-1 subtype does not eliminate systematic geographical variation. International HIV & Hepatitis virus drug resistance workshop & curative strategies. June 8-12, 2010 Dubrovnik, Croatia.
51. S Saravanan, V Madhavan, **R Kantor**, DM Smith, N Kumarasamy, P Balakrishnan, SS Solomon, D Katzenstein, RT Schooley, KH Mayer, S Solomon. Low Prevalence of darunavir resistance mutations among HIV-1-infected patients failing second-line protease inhibitors in South India. XVIII International AIDS Conference, July 18-23, 2010, Vienna, Austria.
52. RM Lloyd, C Loveday, RS Diaz, K Presley, RL Mathis, **R Kantor**, Z Grossman, M Holodniy. Comparison of ViveST™, a Novel Dried Plasma Transportation Matrix, to Frozen Plasma Using a Quantitative HIV-1 Viral Load Assay. American Association for Clinical Chemistry Annual Meeting, July 25-29, 2010; Anaheim, CA.
53. E Dufort, W Nyandiko, A DeLong, K Wools-Kaloustian, S Ayaya, R Vreeman, J Harwell, **R Kantor**. Misclassification of Treatment Failure Using Immunologic and Clinical Monitoring in HIV Infected Children and Adolescents in Western Kenya. The 48th Annual Meeting of IDSA 2010; October 21-24, 2003; Vancouver, BC, Canada.
54. A Mwangi, J Hogan, **R Kantor**, J Carter, A Siika. Effect of cART timing on survival in HIV/TB co-infection in Western Kenya. 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011; Boston, MA.
55. S Land, J Zhou, P Cunningham, A Sohn, T Singtoroj, D Katzenstein, D Sayer, **R Kantor**. Capacity building and predictors of success for HIV drug resistance testing in the Asia Pacific and Africa. International HIV & Hepatitis virus drug resistance workshop & curative strategies. June 7-11, 2011 Los Cabos, Mexico.
56. A Huang, J Hogan, S Istrail, A DeLong, DA Katzenstein, **R Kantor**. First-line Antiretroviral Treatment Effects on Resistance Mutation Prevalence in HIV-1 Subtypes. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011; Rome, Italy.
57. S Sirivichayakul, A DeLong, R Wongkunya, S Mekprasan, A Sohn, K Ruxrungtham, **R Kantor**, P Phanuphak. Increasing HIV drug resistance among recently infected treatment-naïve MSM in Thailand: Results from three years of annual surveillance. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011; Rome, Italy.

58. M Vidya, S Saravanan, S Solomon, **R Kantor**, SS Sunil, KH Mayer, N Kumarasamy, W Greer, D Katzenstein, P. Balakrishnan. HIV-1 genotypic resistance pattern in children exposed to first-line HAART in South India. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011; Rome, Italy.
59. S Saravanan, M Vidya, **R Kantor**, P Balakrishnan, S Solomon, D Katzenstein, N Kumarasamy, KH Mayer, SS Sunil, W Greer, D Smith. HIV-1 reverse transcriptase nucleotide substitutions in subtype C infected drug naïve and treatment experienced patients in South India. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011; Rome, Italy.
60. P Chan, A Rana, Z. Parillo, P Loberti, S Chowdhury, S, N Alexander, CG Beckwith, KT Tashima, KT, TP Flanigan, **R Kantor**. High Rates of Acute HIV Infection Among Recently Diagnosed Students from Rhode Island. 2011 National HIV Prevention Conference. August 14-17, 2011, Atlanta, GA.
61. PA Chan, A Huang, **R Kantor**. Low transmission rates of the reverse transcriptase K65R mutation across different HIV-1 subtypes. The 49th Annual Meeting of IDSA; October 20-23, 2011; Boston, MA, USA.
62. BP Westley, AK DeLong, S Soeung, T Chhraiing, S Dim, EM Dufort, JI Harwell, **R Kantor**. High Rates of Treatment Failure Misclassification using 2010 vs. 2006 WHO Guidelines among HIV-infected Children in Siem Reap, Cambodia. The 49th Annual Meeting of IDSA; October 20-23, 2011; Boston, MA, USA.
63. KK Venkatesh, AK DeLong, **R Kantor**, S Chapman, J Ingersoll, J Kurpewski, MP De Pasquale, R D'Aquila, AM Caliendo, S Cu-Uvin. HAART-experienced women with detectable plasma viral load continue to have genital tract HIV-1 RNA shedding despite changing treatment regimens in a clinical care program. The 49th Annual Meeting of IDSA; October 20-23, 2011; Boston, MA, USA.
64. M Mann, L Diero, E Kemboi, F Mambo, W Injera, A DeLong, L Schreier, K Wools Kaloustian, N Buziba, **R Kantor**. Unplanned Antiretroviral Treatment Interruptions Induced by the Kenyan Post-Election Crisis are Associated with HIV virologic Failure. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012; Seattle, Washington, USA.
65. B Westley, A DeLong, T Chhraiing, S Dim, E Nerrienet, L Schreier, J Hogan, **R Kantor**. Extensive Drug Resistance in HIV-Infected Cambodian Children Failing First-Line Antiretroviral Therapy is Undetected by WHO 2010 Guidelines. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012; Seattle, Washington, USA.
66. A Jiamsakul, **R Kantor**, PCK Li, S Sirivichayakul, T Sirisanthana, P Kantipong, C Lee, A Kamarulzaman, W Ratanasuwana, R Ditangco, T Singtoroj, S Sungkanuparph on behalf of the TREAT Asia Studies to Evaluate Resistance – Monitoring Study (TASER-M). Comparison of Predicted Susceptibility between Genotype and Virtual Phenotype HIV Drug Resistance Interpretation Systems among Treatment-naïve HIV-infected Patients in Asia: TASER-M Cohort Analysis. International Workshop on HIV&Hepatitis Virus, Drug Resistance and Curative Strategies; June 5-9, 2012; Sitges, Spain.
67. S Saravanan, V Madhavan, **R Kantor**, S Sivamalar, S Gomathi, S Solomon, SN Mothi, N Kumarasamy, P Selvamuthu, A Pradeep, DM Smith, S Solomon, P Balakrishnan. Rilpivirine and etravirine resistance among HIV-1 subtype C infected Children failing non-nucleoside reverse transcriptase inhibitor-based regimens in South India. XIX International AIDS Conference, Washington, D.C., 22-27 July 2012.
68. S Saravanan, V Madhavan, **R Kantor**, DM Smith, S Gomathi, S Sivamalar, B Sweetha, S Solomon, KG Murugavel, SN Mothi, N Kumarasamy, P Selvamuthu, S Solomon, P Balakrishnan. Differences in Evolution of HIV-1 Subtype C Reverse Transcriptase Gene between Children and Adults Likely Explained by Maturity of Cytotoxic T-Lymphocyte Responses. XIX International AIDS Conference, Washington, D.C., 22-27 July 2012.
69. **R Kantor**, L Schreier, R Lloyd, S Saravanan, N Kumarasamy, S Sirivichayakul, P Phanuphak, Y Wu, F Zhang, F Mambo, L Diero, M Balamane, A DeLong, D Katzenstein. Sampletanker and plasma genotyping of diverse HIV-1 subtypes from multiple geographic regions. XIX International AIDS Conference, Washington, D.C., 22-27 July 2012.

70. T Rogo, AK DeLong, PA Chan, **R Kantor**. High Levels of Diversity and Drug Resistance in the Only Pediatric HIV Clinic in Rhode Island. The 50th Annual Meeting of IDSA; October 17-21, 2012; San Diego, CA, USA.
71. **R Kantor**, L Smeaton, S Vardhanabhuti, S Tripathi, MG Morgado, S Saravanan, CL Wallis, S Hudelson, T Campbell, S Eshleman. Baseline HIV Drug Resistance is Independently Associated with Virologic Failure in the Multi-national PEARLS (ACTG A5175) Study. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, GA.
72. P Chan, A Huang, M Salemi, M Prosperi, M Reitsma, **R Kantor**. Chronic Infections Drive HIV Transmission Networks among High-Risk Populations. 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, GA.
73. K Olshtain-Pops, L Schreier, Z Grossman, M Korem, S Maayan, **R Kantor**. Resistance to Protease Inhibitors in HIV-1 Subtype C from Patients of Ethiopian Origin Treated at Hadassah AIDS Center. The Israeli Infectious Diseases Society Annual Meeting, February 14-15, 2013, Israel.
74. T Liu, JW Hogan, L Wang, S Zhang, **R Kantor**. Optimizing Diagnosis of HIV Treatment Failure under Constrained availability of Viral Load Testing. 17th International Workshop on HIV Observational Databases. April 11-13, 2013; Cavtat, Croatia.
75. A Huang, DA Katzenstein, S Saravanan, Y Wu, S Sirivichayakul, N Kumarasamy, F Zhang, P Phanuphak, **R Kantor**. Differential First-Line Antiretroviral Therapy Resistance in HIV-1 Non-B Subtypes in India, China, and Thailand. 22nd International HIV Drug Resistance Workshop, June 4-8, 2013; Toronto, Canada.
76. D Aguiar, A Huang, **R Kantor**, S Istrail. Haplotype assembly in the presence of hemizygosity, haplotype sharing, polyploidy, and viral quasispecies. High Throughput Sequencing Algorithms and Applications. July 19-20, 2013, Berlin, Germany.
77. L Diero, A DeLong, L Schreier, E Kemboi, M Orido, M Rono, M Reitsma, W Emonyi, N Buziba, J Hogan, **R Kantor**. High HIV Resistance and Mutation Accrual at low Viral Loads upon 2nd-Line Failure in Western Kenya. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014; Boston, MA.
78. PA Chan, A Huang, AK DeLong, JW Hogan, M Reitsma, M Salemi, **R Kantor**. Phylogenetic Investigation of HIV Transmission Dynamics over Time Reveals 'Active' Clusters of Men who Have Sex with Men. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014; Boston, MA.
79. L Hu, J Hogan, A Mwangi, EJ Carter, B Musick, **R Kantor**, A Siika. Estimating Causal Effect of Treatment Timing from EHR Data with Censoring in Exposure and Outcome: Application to Timing of cART Initiation in HIV/TB Co-infection. 18th International Workshop on HIV Observational Databases, March 27-29, 2014; Sigtes, Spain.
80. **R Kantor**, A DeLong, M Balamane, L Schreier, RM Lloyd, W Injera, L Kamle, F Mambo, S Muyonga, D Katzenstein, J Hogan, N Buziba, L Diero. HIV Diversity and Drug Resistance from Plasma and Non-Plasma Analytes in a Large Treatment Program in Western Kenya. 23rd International HIV Drug Resistance Workshop, June 3-4, 2014; Berlin, Germany.
81. W Nyandiko, R Vreeman, S Wakoli, L Schreier, L Diero, J Songok, S Ayaya, **R Kantor**. High Levels of Drug Resistance among HIV Infected Children after Failure of Prevention of Mother to Child Transmission in Western Kenya. 20th International AIDS Conference, July 20-25, 2014; Melbourne, Australia.
82. S Saravanan, S Gomathi, S Sivamalar, P Selvamuthu, N Kumarasamy, P Balakrishnan, SS Solomon, S Solomon, S Cu-Uvin, **R Kantor**. High Discordance in Plasma and Genital Tract Resistance in Indian Women Failing 1st-Line Therapy. 20th International AIDS Conference, July 20-25, 2014; Melbourne, Australia.
83. T Liu, J Hogan, R Huang, **R Kantor**. Improved Viral Load Monitoring Capacity with Rank-Based Algorithms for Pooled Assays. Conference on Retroviruses and Opportunistic Infections, February 23-26, 2015; Seattle, WA.
84. K Brooks, L Diero, A DeLong, M Balamane, M Reitsma, E Kemboi, M Orido, M Coetzer, J Hogan, **R Kantor**. Viral Failure and High K65R in Kenyan Patients on Tenofovir-Based 1st-Line Therapy. Conference on Retroviruses and Opportunistic Infections, February 23-26, 2015; Seattle, WA.

85. **R Kantor**, K Brooks, M Balamane, L Schreier, M Orido, E Kemboi, M Chepkenja, PA Chan, W Emonyi, L Diero. HemaSpot™: a Novel Blood Storage Device for HIV Drug Resistance Testing. 24th International HIV Drug Resistance Workshop, February 21-22, 2015; Seattle, WA.
86. K Olshtain-Pops, A Kassu, S Maayan, D Mekonnen, S Yifru, L Schreier, F Maldarelli, Z Grossman, **R Kantor**. High HIV Drug Resistance in Naïve, Recently Diagnosed Patients in Gondar, Ethiopia. 24th International HIV Drug Resistance Workshop, February 21-22, 2015; Seattle, WA.
87. M Coetzer, L Ledingham, L Diero, E Kemboi, M Orido, W Emonyi, **R Kantor**. Alternative Mechanisms of HIV Protease Inhibitor Resistance during 2nd line Failure. 24th International HIV Drug Resistance Workshop, February 21-22, 2015; Seattle, WA.
88. K Brooks, L Diero, A Delong, M Balamane, M Reitsma, E Kemboi, M Orido, M Coetzer, J Hogan, **R Kantor**. Viral Failure and High K65R in Kenyan Patients on Tenofovir-Based 1st-Line Therapy. 24th International HIV Drug Resistance Workshop, February 21-22, 2015; Seattle, WA.
89. KK Tee, **R Kantor**, S Sungkanuparph, Y Takebe, P Li, R Ditangco, P Phanuphak, T Sirisanthana, B Sim, W Ratanasuwana, P Kantipong, M Mustafa, TP Merati, A Jiamsakul, T Singtoroj, A Kamarulzaman. Transmission networks of HIV-1 among men who have sex with men in East and Southeast Asia. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 19-22 July 2015, Vancouver, Canada.
90. R Reece, M D'Antuono, K Tashima, **R Kantor**. Pre-switch Resistance to Complera and Stribild and its Impact on HIV Virological Outcome. IDWeek, October 7-11, 2015, San Diego, CA.
91. J Gregson, M Tang, N Ndembu, RL Hamers, VC Marconi, E Raizes, **R Kantor**, RW Shafer, RK Gupta, On behalf of TenoRes investigators. Global tenofovir resistance following 1st line regimens for adult HIV-1 infection. Conference on Retroviruses and Opportunistic Infections, February 22-25, 2016; Boston, MA.
92. S Saravanan, TR Dinesha, S. Poongulali, N Kumarasamy, SS Solomon, L Ledingham, A Derache, M Coetzer, D Katzenstein, **R Kantor**. HIV RNA/DNA Drug Resistance in Naïve and Tenofovir-treated Patients in Chennai, India. 25th International HIV Drug Resistance Workshop, February 20-21, 2016; Boston, MA.
93. M Coetzer, L Ledingham, L Diero, E Kemboi, M Orido, W Emonyi, **R Kantor**. Longitudinal Evaluation of Coreceptor Use in Human Immunodeficiency Virus 1 Subtype A in Western Kenya. 25th International HIV Drug Resistance Workshop, February 20-21, 2016; Boston, MA.
94. S Saravanan, TR Dinesha, S. Poongulali, N Kumarasamy, SS Solomon, L Ledingham, A Derache, P. Balakrishnan, M Coetzer, D Katzenstein, **R Kantor**. A point mutation resistance assay to optimize HIV-1 subtype C antiretroviral therapy in India. 21st International AIDS Conference, Durban, South Africa, 18-22 July 2016.
95. **R Kantor**, S Vardhanabhuti, S Tripathy, M Morgado, S Saravanan, C Wallis, SE Hudelson, SH Eshleman, T Campbell. Association between baseline and failure HIV drug resistance in the ACTG PEARLS study. Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, Washington.
96. Y Xu, T Liu, **R Kantor**, A Mwangi, MJ Daniels, JW Hogan. Classification using Ensemble Learning under Weighted Misclassification Loss. Joint Statistics Meetings, July 29-August 3, 2017, Baltimore, MD.
97. A Guang, C Dunn, M Howison, M Coetzer, L Ledingham, M D'Antuono, PA Chan, **R Kantor**. Preserving intra-patient variance improves phylogenetic inference of HIV transmission networks. 24th HIV Dynamics & Evolution Conference, May 23-26, 2017, Isle of Skye, Scotland.
98. T Liu, JW Hogan, MJ Daniels, M Coetzer, Y Xu, G Bove, AK DeLong, M Orido, L Diero, **R Kantor**. Marker-assisted HIV-1 viral load pooling deconvolution improves monitoring capacity. 9th IAS Conference on HIV Science, 23-26 July 2017, Paris, France.
99. W Nyandiko, R Vreeman, AK DeLong, M Coetzer, E Sang, C McAteer, J Aluoch, M Orido, S Sam, A Caliendo, S Ayaya, JW Hogan, **R Kantor**. HIV-1 Treatment Failure and Extensive

- Drug Resistance in Perinatally-Infected Children Failing 1st-Line Antiretroviral Therapy in Western Kenya. 26th International HIV Drug Resistance Workshop, November 6-8, 2017; Johannesburg, South Africa.
100. S. Goodrich, A. Gardner, C. Ngetich, S. Ali, J. Humphrey, B. Jakait, **R. Kantor**. Good short-term outcomes despite extensive pre-3rd-line HIV drug resistance in Kenya. 22nd International AIDS Conference, 23-27 July 2018, Amsterdam, Netherlands.
 101. R. Vreeman, W. Nyandiko, A. DeLong, M. Coetzer, J. Okoyo, C. McAteer, E. Sang, A. Ngeresa, S. Ayaya, J. Hogan, **R Kantor**. Characterizing adherence and drug level effects on viral outcomes in HIV-infected Kenyan children. 22nd International AIDS Conference, 23-27 July 2018, Amsterdam, Netherlands.
 102. Cunha MS, Corrêa IA, Coetzer M, Diero L, Orido M, Tanuri A, Costa LJ, **Kantor R**. Unrecognized protease inhibitor drug resistance mutations in HIV-1 subtype A. 22nd International AIDS Conference, 23-27 July 2018, Amsterdam, Netherlands.
 103. A. Noska, T. Liu, I. Kuo, M. Coetzer, A. Kurth, **R Kantor**, C. Beckwith. Validity of Self-Reported HCV Status among Justice-Involved Persons Living with HIV. IDWeek, October 3-7, 2018, San Francisco, CA.

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

PEER-REVIEWED

NON-PEER REVIEWED

1. **R Kantor**. TREAT Asia workshop explores drug resistance. TREAT Asia Report, July 2005. <http://www.amfar.org/cgi-bin/iowa/asia/news/index.html?record=57>
2. **R Kantor**, D Katzenstein. Antiretroviral Drug Resistance in Non-Subtype B HIV-1 Isolates from Treated Patients. <http://www.hivresistanceweb.com/>.
3. **R Kantor**. Antiretroviral drug resistance evolution in the context of HIV diversity. The YRG Care HIV/AIDS Newsletter, February 2009; 2(1):1-2.
4. Political turmoil affects HIV treatment. <https://news.brown.edu/pressreleases/2013/03/conflict>
5. Political turmoil affects HIV treatment. <http://www.theatlanticwire.com/national/2013/03/babies-are-evil-just-us/63028/>
6. HIV Treatment Hindered by Political Strife. <http://scienceblog.com/61050/political-strife-undermines-hiv-treatment/>
7. Department of Medicine Newsletter; Summer 2013. Kantor research awards. <http://www.brownmedicine.org/2/welcome/newsletters/august2013.pdf>
8. Virulence Profile: **R Kantor**. *Virulence* 2014;5:581-584. PMID 24804839. PMC 4063819.
9. Grant supports use of data science to optimize HIV care. <http://news.brown.edu/articles/2014/12/kenya>
10. National Institutes of Health Grant to Fund Optimization of HIV Treatment: A Q&A with Rami Kantor, MD. <http://www.miriamhospital.org/Newsroom/News.aspx?NewsId=68936/National-Institutes-of-Health-Grant-to-Fund-Optimization-of-HIV-Treatment:-A-Q&A-with-Rami-Kantor-MD/>
11. Department of Medicine Newsletter; Summer 2015. Grant supports data science to optimize HIV care. <http://www.brownmedicine.org/2/welcome/newsletters/summer2015.pdf>
12. Team describes rapid, sensitive test for HIV mutations. October 2015. <https://news.brown.edu/articles/2015/10/hivrna>.
13. Kantor named to HIV treatment guidelines panel. 3/15/16. <https://news.brown.edu/articles/2016/03/kantor>

INVITED MEETINGS AND PRESENTATIONS

International

1. Drug resistance testing and interpretation in HIV-1 non-B subtypes. 15th International AIDS Conference, July 12-16, 2004; Bangkok, Thailand.
2. International workshop organizer and Faculty: TREAT Asia workshop on HIV drug resistance. October 12-13, 2004. Chulalongkorn University, Bangkok, Thailand.
3. Mechanisms of HIV drug resistance; (ii) Drug Resistance Databases and Interpretation. National Consultation on Drug Resistance in Malaria, Tuberculosis, and HIV/AIDS, September 19-21, 2005; Mumbai, India
4. HIV Diversity and Drug Resistance. National Institution of Communicable Diseases Johannesburg, South Africa. September 8, 2005
5. HIV sequence analyses; (ii) HIV sequence databases; (iii) Diversity and origin of HIV; (iv) HIV diversity and drug resistance. HIV TB Bioinformatics Conference Course, September 12-16, 2005; Cape Town, South Africa
6. Organizer and Faculty, Drug Resistance Workshop. September 23, 2005, YRG Care, Chennai, India.
7. Mechanisms of HIV drug resistance; (ii) Drug resistance interpretation. Low cost diagnostics and HIV drug resistance course. June 30-July 1, 2006, Harare, Zimbabwe.
8. HIV sequence quality assessment; (ii) HIV subtypes and drug resistance. South Africa Treatment and Resistance Network (SATuRN) planning meeting, July 4-6, 2006, Johannesburg, South Africa.
9. Sequence analyses quality control; (ii) HIV drug resistance genotypic interpretation. TREAT Asia Quality Assurance Scheme (TAQAS) Meeting, July 11, 2006, Bangkok, Thailand
10. HIV data curation and analyses; (ii) HIV drug resistance mutation lists. Second South Africa Treatment and Resistance Network (SATuRN) meeting, June 4-5, 2007, Durban, South Africa.
11. Report of TAQAS meeting; (ii) Phenotypic study of drug resistance in HIV-1 non-B subtypes. 7th Annual TREAT Asia Network Meeting, September 7-10, 2007, Hanoi, Vietnam.
12. Base calling in HIV sequences; (ii) Technical issues with HIV-1 non-subtype B genotyping. TREAT Asia Quality Assurance Scheme Workshop, September 5, 2007, Bangkok, Thailand.
13. Principles of HIV drug resistance and interpretation. Chennai HIV antiretroviral treatment symposium (CART 2008); January 12, 2008; Chennai, India.
14. Principles in HIV drug resistance and interpretation. Kenya Medical Research Institute; April 16, 2008, Nairobi, Kenya.
15. HIV diversity and drug resistance in Western Kenya. Annual review meeting 2008 University of Nairobi STD/AIDS collaborative group; April 14-19, 2008, Nairobi, Kenya.
16. HIV drug resistance in multiple HIV subtypes within IEDEA. International Epidemiological Databases to Evaluate AIDS Executive Committee Meeting. August 1-2, 2008, Cuernavaca, Mexico.
17. HIV diversity and drug resistance. Workshop for HIV drug resistance in clinical practice. September 5, 2008, Cape-Town, South Africa.
18. HIV drug resistance research capacity building within TREAT Asia. 8th Annual TREAT Asia Network Meeting, October 17-19, 2008, Chiang-Mai, Thailand.
19. HIV drug resistance sequencing from filter paper. TREAT Asia Quality Assurance Scheme Workshop, October 15-16, 2008, Bangkok, Thailand.
20. Session Chair and Presenter: Epidemiology and principles of HIV drug resistance. Chennai HIV antiretroviral treatment symposium (CART 2009); January 9-10, 2009; Chennai, India.
21. Faculty and Presenter: TREAT Asia Resistance Data Management and Biostatistics Training Workshop; June 22-25, 2009, Bangkok, Thailand.
22. Improving HIV drug resistance sequencing and interpretation. 9th Annual TREAT Asia Network Meeting, October 10-13, 2009, Bangkok, Thailand.
23. Evolution and patterns of drug resistance in HIV-1 subtype C. Chennai HIV antiretroviral treatment symposium (CART 2010); January 9-10, 2010; Chennai, India.
24. AMPATH Research Program Strategic Planning Retreat; January 28-29, 2010; Eldoret, Kenya.

25. HIV Drug Resistance Workshop; March 19-20, 2010; National AIDS Research Institute; Pune, India.
26. TASER (TREAT Asia Surveillance to Evaluate Resistance) Steering Committee meeting; March 25, 2010; Bangkok, Thailand.
27. LAASER (Linked Asia-Africa Surveillance to Evaluate Resistance) Scientific Advisory Board meeting, May 27, 2010; Amsterdam, Netherlands.
28. TREAT Asia Quality Assurance Scheme steering committee meeting; October 10, 2010, Bangkok, Thailand.
29. Faculty and Organizer: Second TREAT Asia HIV Drug Resistance Training Workshop; October 11-12, 2010, Bangkok, Thailand.
30. HIV diversity and drug resistance in subtype C. 5th South African HIV Drug Resistance and Treatment Monitoring Workshop, University of the Free State, 27-29 October, Bloemfontein, South Africa.
31. Drug resistance in HIV first line antiretroviral failure. Chennai HIV antiretroviral treatment symposium (CART 2011); January 8-9, 2011; Chennai, India.
32. TREAT Asia Quality Assurance Scheme (TAQAS). TREAT Asia Studies to Evaluate Resistance Meeting; Annual Network Meeting; November 9-11, 2011, Chiang-Mai, Thailand.
33. HIV drug resistance to first-line antiretroviral therapy. Chennai HIV antiretroviral treatment symposium (CART 2012); January 21-2, 2012; Chennai, India.
34. HIV diversity and drug resistance. HIV Science 2012 international symposium on HIV and infectious diseases; January 20-22, 2012; Chennai, India.
35. HIV diversity and drug resistance. November 1, 2012; University of Ghana Medical School, Accra, Ghana.
36. Resistance to second line antiretroviral therapy. Chennai HIV antiretroviral treatment symposium (CART 2013); February 9, 2013; Chennai, India.
37. 13th Annual TREAT Asia Network Meeting, October 10-11, 2013, Phuket, Thailand.
38. HIV Diversity and the Evolution of Drug Resistance. 2nd International Science Symposium on HIV and Infectious Diseases (HIV Science 2014); January 30 - February 1, 2014, Chennai, India.
39. HIV drug resistance: where will it lead to?. Chennai HIV antiretroviral treatment symposium (CART 2014); April 26-27, 2014; Chennai, India.
40. Use of Point Mutation Assays for Resistance Testing in India: Challenges and Benefits NIH- and African Society of Laboratory Medicine- sponsored Collaborative Meeting on Defining Key HIV-1 Mutations for Determining Antiretroviral Resistance in Low and Middle Income Countries. December 5–6, 2014; Cape Town, South Africa.
41. Drug resistance profile among antiretroviral experienced individuals and their implication; Speaker and Session Chair. 7th National Conference of AIDS Society of India- ASICON Kolkata, India; 12-14 December 2014.
42. HIV drug resistance: what's new? Chennai HIV antiretroviral treatment symposium (CART 2015); March 28-29, 2015; Chennai, India.
43. World Health Organization Annual HIV Resistance Network (HIVResNet) Meeting; July 19, 2015, Vancouver, Canada.
44. World Health Organization HIV Resistance Network (HIVResNet) Laboratory Working Group Meeting; July 19, 2015, Vancouver, Canada.
45. Academic Model Providing Access To Healthcare (AMPATH) Research Retreat; October 8-9, 2015, Eldoret, Kenya.
46. What's new in HIV drug resistance? Invited Speaker and Session Chair. 8th National Conference of AIDS Society of India- ASICON, 29 October - 1 November 2015, Mumbai, India (trip cancelled due to flight cancellations).
47. (i) Antiretroviral drug resistance in developing countries; (ii) HIV drug resistance in pre-exposure prophylaxis settings. Chennai HIV antiretroviral treatment symposium (CART 2016); April 16-17, 2016; Chennai, India.
48. HIV Drug Resistance: What's New? 9th National Conference of the AIDS Society of India – ASICON, Mumbai, India; 7-9 October, 2016.
49. Point mutations assays and resistance testing in HIV management. 9th National Conference of the AIDS Society of India – ASICON, Mumbai, India; 7-9 October, 2016.

50. Session Chair. 9th National Conference of the AIDS Society of India – ASICON, Mumbai, India; 7-9 October, 2016.
51. Pretreatment HIV drug resistance is associated with treatment outcomes. Invited presentation in a WHO Webinar entitled 'Considering Programmatic Implications of Rising Levels of HIV Drug Resistance: Finalizing the Global Action Plan'; December 12, 2016.
52. (i) Point mutation assays and drug resistance testing in HIV management; (ii) Alternative mechanisms of HIV drug resistance. Chennai HIV antiretroviral treatment symposium (CART 2017); March 25-26, 2017; Chennai, India.
53. HIV Drug Resistance in Resource Limited Settings; Key Plenary Lecture. 10th National Conference of the AIDS Society of India – ASICON, Hyderabad, India; 6-8 October, 2017.
54. World Health Organization HIV Drug Resistance ResNet Meeting. Johannesburg, South Africa, November 9-10, 2017.
55. Low abundance drug resistance variants: what is a meaningful threshold for reporting? Mini-symposium on Bioinformatics strategies for NGS-based HIV drug resistance testing. National Microbiology Laboratory, Public Health Agency of Canada; Winnipeg, Manitoba, Canada; February 21-22, 2018.
56. Dolutegravir drug resistance and genetic barrier. Chennai HIV antiretroviral treatment symposium (CART 2018); April 28-29, 2018; Chennai, India.

National

1. HIV drug resistance surveillance and monitoring. September 21, 2007, Centers for Disease Control, Atlanta, Georgia, USA.
2. World Health Organization HIV Resistance Network Laboratory Network Meeting; March 3, 2013; Atlanta, Georgia.
3. HIV-1 RNA Levels and Drug Resistance in Blood and Non-Blood Compartments from Infected Men and Women enrolled in ACTG A5077. 2014 Annual AIDS Clinical Trials Group Network Meeting; June 24, 2014; Washington DC, USA.
4. External Advisory Committee meeting, University of Washington Center for AIDS Research; July 23-24, 2015, Seattle, WA.
5. Annual Retreat of the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. April 6, 2016, Rockville, MD.
6. Consultation on Global Trends of HIV Drug Resistance. May 3-4, 2016; National Institute of Allergy and Infectious Diseases; NIH; Rockville, MD.
7. Low Cost Nucleic Acid Testing - Solving the Sample Prep Problem Convening. Bill & Melinda Gates Foundation. June 28-29, 2016, Seattle, WA.

Regional/Local

1. Drug resistance in HIV-1 non-subtype B sequences. 9th International Workshop on Virus Evolution and Molecular Epidemiology, Stanford University, Stanford, California, USA. August 14, 2003.
2. HIV diversity and drug resistance. February 17, 2006, Center for Biostatistics for AIDS Research, Harvard School of Public Health, Harvard University, Boston, MA.
3. South African Treatment and Resistance Network meeting; February 3, 2008; Boston, MA
4. World Health Organization HIVResNet HIV Drug Resistance Surveillance Mutations Working Group; February 2, 2008; Boston, MA.
5. HIV update: progress and challenges. American Society of Clinical Laboratory Science: Central New England. May 6-8, 2008, Providence, RI, USA.
6. HIV Drug Resistance and Global Diversity. School of Public Health Bioinformatics Core, Harvard University; April 13, 2010; Boston, MA.
7. World Health Organization HIV Resistance Network Laboratory Working Group Meeting; March 2, 2014; Boston, Massachusetts.
8. World Health Organization Annual HIV Drug Resistance (HIVResNet) Meeting; March 3, 2014; Boston, Massachusetts.

9. HIV Drug Resistance: A Global Challenge. Memorial Hospital Medical Grand Rounds; 1 April 2015; Pawtucket, RI; USA.
10. Lifespan/Brown/Tufts Center for AIDS Research Scientific Advisory Committee Meeting; October 2, 2015, Providence, RI, USA.
11. HIV drug resistance: a global challenge. Bruce Selya Excellence in Research Awardee Speaker; The Lifespan 23rd Annual Research Celebration, October 29, 2015, Providence, RI.
12. The Global HIV Drug Resistance Challenge. Can Biotechnology Help? Biotechnology and Global Health Symposium, February 11, 2016; Brown University, Providence, RI, USA.
13. HIV Drug Resistance: A Global Challenge. Guest lecture; 4/25/16; BIOL 0180, 'The Biology of AIDS' Course, Brown University.
14. HIV Drug Resistance: Global Challenges and Needs. ENGN 1930L; Biomedical Engineering, Design, Research and Modeling Course, Brown University; September 7, 2016.
15. Global challenges in HIV Drug Resistance and what we can do about it. Infectious Diseases Grand Rounds, Boston University, September 29, 2016.
16. The Global HIV Drug Resistance Challenge. Can Biotechnology Help? BIOL 1070; Biotechnology and Global Health, Brown University; November 15, 2016.
17. HIV Drug Resistance. Stanley Street Treatment and Resources Clinics, Fall River, MA; September 18, 2017.
18. The Global HIV Drug Resistance Challenge. Can Biotechnology Help? Guest lecture, BIOL 1070; Biotechnology and Global Health, Brown University; October 24, 2017.
19. HIV Drug Resistance: A Global Challenge. Guest lecture; 11/27/17; BIOL 0180, 'The Biology of AIDS' Course, Brown University.
20. HIV career, research and challenges. HIV Prevention graduate seminar (PHP2330); Brown University, Providence, RI; 2/14/18.
21. Physicians involvement in global health; Primary Care Population Medicine (PCPM) Program for Medical Students, Brown University Alpert Medical School, Providence, RI, 8/2/18.

GRANTS

CURRENT GRANTS

1. Real time phylogeny and contact tracing to disrupt HIV transmission. NIH R01 (AI136058); 2017-2022; role – Principal Investigator.
2. HIV drug resistance, monitoring and transmission. NIH K24 (AI134359); 2017-2022; role – Principal Investigator.
3. Optimizing HIV Treatment Monitoring Strategies under Resource Constraints. NIH R01 (AI108441); 2014-2019; role-Principal Investigator.
4. Failure and resistance in Kenyan children. NIH R01 (AI120792); 2016-2020; role – Principal Investigator
5. Resistance in HIV subtypes in Brazil. Brown Brazil initiative; 2015-2017; role-Principal Investigator.
6. East Africa International Epidemiological Databases to Evaluate AIDS (IEDEA) Regional Consortium. NIH (U01AI069911; Wools Principal Investigator); 2016-2021; role – co-Investigator.
7. Providence-Boston Center for AIDS Research, Basic Science Core; NIH Program Grant (P30AI042853; Cu-Uvin Principal Investigator); 1998-2017; role – Core Co-Director.
8. Combining social network, spatial and phylogenetic approaches to identify new HIV infections. NIH R21 (AI131979; Rudolph Principal Investigator); 2017-2019; role – co-Investigator.

GRANT APPLICATIONS SUBMITTED

1. Treatment failure and drug resistance in HIV-1 subtype C infected individuals starting dolutegravir-based first line therapy in India (Indo-US grant; CRDF Global).

PRIOR GRANTS

1. HIV in Diverse Settings; Focus on Israel. Framework Faculty Curriculum Development Grant; January 2018; role – Principal Investigator.
2. HIV drug resistance in Chennai, India. NIH R21 (AI106392); 2013-2016; role- Principal Investigator.
3. Extended Phylogenetic Inference of HIV Transmission Networks. Brown University DEANs Award; 2014-2015; role-Principal Investigator.
4. A point of Care Platform for HIV Drug Resistance. Brown University Inaugural Translational seed Award; 2013-2014; role-co Investigator.
5. Antiretroviral treatment failure and drug resistance in HIV-infected patients on second line regimens in western Kenya. NIH Center for AIDS Research supplement grant (P30AI042853); 2010-2014; role-co-Investigator, principal researcher.
6. HIV drug resistance in different HIV-1 subtypes. NIH RO1 (AI066922); 2008-2014; role-Principal Investigator.
7. HIV drug resistance in different subtypes. NIH RO1 (AI066922) supplement; 2012-2014; role-Principal Investigator.
8. A point of Care Platform for HIV Drug Resistance. CFAR collaborative grant; 2013; role-co Investigator.
9. HIV-1 Drug Resistance in Plasma and Genital Tract in Southern India. NIH Center for AIDS Research supplement grant (P30AI042853); 2008-2012; role-co-Investigator, principal researcher.
10. HIV-1 genotypic diversity and drug resistance in western Kenya at times of political crisis. NIH IEDEA supplement (U01AI069911); 2008-2012 role-co-Investigator, principal researcher.
11. HIV Genotypic diversity and drug resistance in Western Kenya. Brown/Tufts Center For AIDS Research Developmental Grant (P30AI042853); 2006-2008; role-Principal Investigator.
12. Improving adherence and cognition in substance-using HIV patients. NIH R34 (DA031057); 2010-2012; role-co-Investigator.
13. Kaposi's sarcoma in western Kenya. NIH Fogarty supplement. 2008-2009; role-co-Investigator.
14. HIV drug resistance and treatment outcomes in adults in western Kenya after a period of crisis. The Friendship Foundation; 2008-2010; role-Principal Investigator.
15. HIV diversity and drug resistance in Western Kenya. The Rhode Island Foundation; 2008-2010; role-Principal Investigator.

UNIVERSITY TEACHING ROLES

1. Brown University; BIOL 1980: HIV in Diverse Settings; Focus on Israel; 2018 winter session course. Role – course developer and leader.
2. Mentoring and training

Undergraduate Students

2008	Jacklyn Katz; Columbia University
2009	Orli Mintz; Brandeis University
2010	Shahzeb Kazi; University of Connecticut
2010 – 2011	Colette DeJong (Brown University); Amaad Rana (Emory University); Ilyse Blazar (Tulane University)
2011 – 2012	Matthew Tay (Brown University)
2011 -2014	Marissa Reitsma (Brown University)
2014 -2015	Lauren Ledingham (Brown University)
2014 – 2017	Matthew D'Antuono (Brown University)
2015	Ferdinand Mayer (Brown University)
6-8/2016	Elana Pyfrom (Brown University)
2018 -	Cindy Won (Brown University)

Graduate Students

2005 - 2008	Vidya Sundararajan, PhD candidate, Madras University, Chennai, India
2005 – 2006	Katharine Schulze; Brown University Medical Student
2006	Edelwisa Segubre; Brown University Philippines Fogarty fellow
2009 – 2010	Lakshmi Rajesh; PhD candidate, Madras University, Chennai, India
2009 – 2010	Brady Tang; Masters candidate, Center for Statistical Sciences, Brown University
2009 – 2011	Ann Mwangi, PhD Candidate, Center for Statistical Sciences, Brown University; Member, PhD Dissertation Committee
2010 – 2012	Kenneth Morabito, PhD Candidate, Department of Engineering, Brown University; Member, PhD Dissertation Committee
2010	Ziad El-Khatib, PhD candidate, Karolinska Institute, Stockholm, Sweden
2010 – 2012	Marita Mann, Masters in Public Health candidate, Brown University
2012 – 2014	Maya Balamane, Masters in Public Health candidate, Brown University
2013	Millicent Orido, AMPATH Reference Laboratory, Eldoret, Kenya
2013 - 2015	Liangyuan Hu, PhD Candidate; Center for Statistical Sciences, Brown University Member, PhD Dissertation Committee
2013	Sheela Krishnan, Brown University MD candidate
2014 – 2015	Katherine Brooks, Brown University MD candidate
2014 -	Yizhen Xu, PhD Candidate, Center for Statistical Sciences, Brown University Member of Dissertation Committee
2014 -	August Guang, PhD Candidate, Ecology and Evolutionary Biology, Brown University
2016	Isadora Alonso, Masters candidate, Federal University of Rio de Janeiro, Brazil
2016 - 2017	Anna Makaretz, Masters Candidate, School of Engineering, Brown University
2017 -	Rachel Deraney, PhD Candidate, Brown University School of Engineering

Post-doctoral Fellows

2007 - 2011	Philip Chan MD, Brown University Medicine resident, Infectious Diseases and T32 Fellow.
2008 – 2010	Elizabeth Dufort MD, Brown University Pediatric Infectious Diseases Fellow
2009 – 2013	Austin Huang PhD, Post-doctoral Fellow; Brown University Division of Infectious Diseases
2010 – 2011	Benjamin Westley MD, Brown University Infectious Diseases Fellow
2010 – 2013	Tanya Rogo MD, Brown University Pediatric Infectious Diseases Fellow
2015 – 2016	Rebecca Reece MD, Brown University Infectious Diseases Fellow
2017 -	Su Aung MD, Brown University Infectious Diseases Fellow

Faculty

2005 - 2007	Pachamuthu Balakrishnan PhD, Director of Laboratories, YRG CARE, Chennai, India
2008 – 2010	Winston Nyandiko MD, Senior Lecturer; and AMPATH Associate Program Manager-Research, Moi University, Eldoret, Kenya
2009 – 2013	Shanmugam Saravanan PhD, HIV Drug Resistance Laboratory Director, YRG CARE, Chennai, India
2009 - 2012	Tao Liu PhD, Assistant Professor, Brown University Center for Statistical Sciences
2011 - 2013	Joao Tavares MD, T32 Fellow, The Miriam Hospital, Brown University;
2010 -	Kwamena Sagoe PhD, Lecturer, University of Ghana Medical School, Accra, Ghana
2011 - 2015	Philip Chan MD, Assistant Professor, Division of Infectious Diseases, Brown University; Primary Mentor, K-23 Award
2012	Karen Olshtain-Pops MD, Assistant Professor, Hadassah Medical Center, Jerusalem, Israel
2011 - 2013	Mia Coetzer PhD, Assistant Professor (Research), Division of Infectious Diseases, Brown University

2013 - 2017	Suzanne Goodrich MD, Assistant Professor, Division of Infectious Diseases, Indiana University
2014 - 2015	Nicole Alexander MD, Assistant Professor of Medicine, Division of Infectious Diseases, Brown University
2016 -	Sabina Holland MD, Brown University Pediatric Infectious Diseases Division
2016 -	John Humphrey MD, Indiana University Division of Infectious Diseases
2016 -	Shamim Ali MD, Moi University Department of Medicine, Eldoret, Kenya

HOSPITAL TEACHING ROLES

1999	Medical students' tutor Internal Medicine Sheba Medical Center, Israel
1999 - 2000	Lecturer Infectious Diseases Course Sheba Medical Center Nursing School, Israel
2007 -	Lifespan/Brown University Infectious Diseases Fellows Lecture Series <i>1-2 lectures per year on HIV drug resistance</i>
2008 -	International Infectious Diseases Brown University Internal Medicine Residency applicants <i>Up to 12 lectures per year on international infectious diseases at Lifespan/Brown</i>
2008 -	Teaching of Brown University internal medicine residents and medical students on the Immunology (HIV) inpatient service, The Miriam Hospital, Providence, RI
2008 -	Teaching of Brown University internal medicine residents and medical students in the Immunology (HIV) outpatient clinic, The Miriam Hospital, Providence, RI
2008 – 2010	Member Scholarship Oversight Committee Dr. Elizabeth Dufort Pediatric Infectious Diseases Fellow Lifespan/Brown University
2011 – 2013	Member Scholarship Oversight Committee Dr. Tanya Rogo Pediatric Infectious Diseases Fellow Lifespan/Brown University